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Placental insufficiency is commonly associated with intrauterine growth 
restriction, preeclampsia, and spontaneous abortion. The essential nutrient choline 
may mitigate some of these impairments, as suggested by data in humans and 
trophoblast cell culture. Choline is a precursor for several molecules with crucial roles 
during pregnancy: the methyl donor betaine, the neurotransmitter acetylcholine, and 
the phospholipid phosphatidylcholine. Through betaine, it participates in the metabolic 
network referred to as one-carbon metabolism which is essential for many biochemical 
processes including nucleotide synthesis, DNA methylation, and amino acid 
metabolism. Demand for one-carbon (methyl) nutrients, including choline, folate, and 
vitamin B-12, is high during pregnancy when cells of the placenta and fetus undergo 
rapid division. This dissertation research sought to examine the effects of choline 
supplementation during pregnancy in the Dlx3+/- mouse, a model of placental 
insufficiency. 
Study 1 investigated the effects of maternal choline supplementation (MCS) on 
pregnancy outcomes in Dlx3+/- mice. This study demonstrated that maternal choline 
supplementation led to a marked increase in fetal growth by mid-gestation, which 
resulted in compensatory mechanisms to slow growth by downregulating Igf1. 
Placental betaine concentrations were strongly predictive of fetal weights, suggesting 
betaine supply may be a determinant of fetal growth. 
 Study 2 explored the effects of MCS on markers of placental function in the 
Dlx3+/- mouse. The main findings indicate that a higher maternal choline intake can 
alter placental labyrinth size, modulate expression of angiogenic and inflammatory 
genes in the placenta, and decrease placental apoptosis; and that these effects occur in 
a fetal sex-dependent manner. 
Study 3 assessed the effects of MCS on vitamin B-12 status in mice with and 
without placental insufficiency. In addition, data from a human feeding study was 
used to further explore this relationship. MCS increased the active form of vitamin B-
12 in pregnant women; genetic variants that increase choline requirements were also 
shown to alter vitamin B-12 markers.  
Taken together, these studies suggest that higher levels of choline intake 
during pregnancy may be beneficial for the mother and fetus, and provide support for 
further research on the use of choline for improving placental function and mitigating 
placental insufficiency. 
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PREFACE 
 
Choline is an essential nutrient that is required for the synthesis of several 
molecules with crucial roles during pregnancy: betaine, an osmolyte and methyl 
donor; acetylcholine, a neurotransmitter and signaling molecule; and 
phosphatidylcholine (PC), the most prevalent membrane phospholipid. Higher intake 
of choline during pregnancy has previously been shown to downregulate sFlt-1, a 
biomarker of preeclampsia; additionally, choline deficiency in a placental cell culture 
model has been found to impair angiogenesis and increase inflammation and 
apoptosis. 
Given the previous findings suggesting the importance of choline supply 
during healthy pregnancy, the overarching goal of this dissertation was to extend this 
work to a model of placental insufficiency, the Dlx3+/- mouse. Dlx3 (distal-less 3 
homeobox) is a transcription factor which is required for normal placental 
development. Mice heterozygous for this gene display inadequate vascularization and 
development of the placental labyrinth, which is the location of nutrient exchange 
between mother and fetus. To characterize the effects of maternal choline 
supplementation (MCS) in the Dlx3+/- mouse, we assessed the following specific 
aims: 
 
Aim 1: To test the hypothesis that maternal choline supplementation (MCS) improves 
pregnancy outcomes in the Dlx3+/- mouse. This aim was accomplished by 
assessments of litter size and resorption rates, morphometric measurements of fetal 
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and placental growth, and analysis of potential metabolic and molecular determinants 
of fetal growth. Results from this study are presented in Chapter 1. 
 
Aim 2: To test the hypothesis that MCS improves placental function in the Dlx3+/- 
mouse. This aim was accomplished by assessing placental morphology and 
remodeling as well as markers of placental apoptosis, angiogenesis, and inflammation. 
Results from these experiments are presented in Chapter 2. 
 
Aim 3: To test the hypothesis that choline supply alters markers of vitamin B-12 status 
in mice with placental insufficiency as well as healthy pregnant women. This aim was 
accomplished by analyzing vitamin B-12 biomarkers by maternal choline 
supplementation status as well as choline genetic variant status. These findings are 
presented in Chapter 3. 
 
This dissertation research yielded 1 published primary research article in a peer-
reviewed journal (Chapter 1) and two original research manuscript that will be 
submitted for publication within the next few weeks (Chapter 2 and 3). 
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CHAPTER 1 
MATERNAL CHOLINE SUPPLEMENTATION ALTERS FETAL GROWTH 
PATTERNS IN A MOUSE MODEL OF PLACENTAL INSUFFICIENCY* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*King JH, Kwan ST(C), Yan J, Klatt KC, Jiang X, Roberson MS, and Caudill MA. 
Maternal Choline Supplementation Alters Fetal Growth Patterns in a Mouse Model of 
Placental Insufficiency, Nutrients. 9 (2017) 765. doi:10.3390/nu9070765. 
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Abstract 
 Impairments in placental development can adversely affect pregnancy 
outcomes. The bioactive nutrient choline may mitigate some of these impairments, as 
suggested by data in humans, animals, and human trophoblasts. Herein, we 
investigated the effects of maternal choline supplementation (MCS) on parameters of 
fetal growth in a Dlx3+/− (distal-less homeobox 3) mouse model of placental 
insufficiency. Dlx3+/− female mice were assigned to 1X (control), 2X, or 4X choline 
intake levels during gestation. Dams were sacrificed at embryonic days E10.5, 12.5, 
15.5, and 18.5. At E10.5, placental weight, embryo weight, and placental efficiency 
were higher in 4X versus 1X choline. Higher concentrations of hepatic and placental 
betaine were detected in 4X versus 1X choline, and placental betaine was positively 
associated with embryo weight. Placental mRNA expression of Igf1 was 
downregulated by 4X (versus 1X) choline at E10.5. No differences in fetal growth 
parameters were detected at E12.5 and 15.5, whereas a small but significant reduction 
in fetal weight was detected at E18.5 in 4X versus 1X choline. MCS improved fetal 
growth during early pregnancy in the Dlx3+/− mice with the compensatory 
downregulation of Igf1 to slow growth as gestation progressed. Placental betaine may 
be responsible for the growth-promoting effects of choline. 
 
3 
Introduction 
 The placenta mediates the delivery of nutrients to the fetus and is thus a major 
determinant of fetal growth [1]. Impairments in placental development can lead to 
placental insufficiency, an inability of the placenta to provide adequate nutrients for 
the fetus, and contribute to adverse pregnancy outcomes, including intrauterine growth 
restriction (IUGR), miscarriage, and preeclampsia [2,3]. At present, very few 
treatment options are available for placental-induced pregnancy complications that 
adversely affect the health of the mother and child. Nutritional therapies represent a 
promising area of research for improving maternal and child health [4], especially 
since some pharmacological treatments may be unsafe during pregnancy. Choline is a 
water-soluble essential nutrient that is necessary for the synthesis of acetylcholine (a 
neurotransmitter), phosphatidylcholine (a membrane phospholipid), and betaine (a 
methyl donor and osmolyte) [5]. During pregnancy, these molecules support rapid cell 
division, govern genomic methylation patterns, and modulate placental and fetal 
development [6]. 
 Choline has previously been shown to reduce a risk factor of preeclampsia, 
sFLT1, in a randomized, controlled feeding trial of maternal choline supplementation 
(MCS) during the third trimester of pregnancy in healthy women [7]. In addition, 
choline has been shown to modulate inflammation, oxidative stress, and apoptosis of 
immortalized human placental trophoblast cells in culture [8] and in normal murine 
pregnancy [9]. Therefore, we hypothesized that choline supplementation would be 
beneficial for pregnancies complicated by placental insufficiency. 
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During pregnancy, the homeodomain-containing transcription factor distal-less 
homeobox 3 (Dlx3) plays a crucial role in the development of the fetal-maternal 
interface [10]. Mice heterozygous for this gene have been shown to display inadequate 
vascularization and development of the placental labyrinth, which is the location of 
nutrient exchange between mother and fetus [11]. Mice that are homozygous null for 
Dlx3 die between embryonic days 9.5 and 12.5 due to placental failure and display 
extremely restricted fetal growth [10]. Heterozygous embryos are viable but have been 
reported to display placental abnormalities, including a reduced invasion of 
trophoblasts and impaired remodeling of maternal spiral arteries as well as increased 
placental oxidative stress and apoptosis within the labyrinth and maternal decidua 
[11]. 
 A major determinant of early placental and fetal growth in both mice and 
humans is the insulin-like growth factor (IGF) axis, consisting of IGF1 and IGF2, their 
receptors IGF1R and IGF2R, and several binding proteins [12]. The placenta 
accumulates IGFs, IGF receptors, and IGF binding proteins, which help mediate the 
transfer of nutrients from placenta to fetus [13]. The IGF1 receptor transduces the 
growth-promoting function of IGFs, while the IGF2 receptor primarily functions to 
sequester and degrade IGF2 and prevent its binding to IGF1R. Accordingly, the 
genetic deletion of IGF1, IGF2, and IGF1R severely reduces fetal growth in mice, 
while the deletion of IGF2R leads to fetal overgrowth [14]. The expression of IGF 
genes as well as the epidermal growth factor receptor (EGFR), which interacts with 
IGF1R [15], has been shown to be modulated by choline supply in various tissues and 
gestational time points of pregnancy [16,17,18]. 
5 
 The present study was undertaken to investigate the effects of MCS on the 
determinants and parameters of fetal growth in the Dlx3 murine model of placental 
insufficiency. We hypothesized that (a) maternal choline supplementation would 
support fetal growth in placental insufficiency and (b) this effect may occur through 
the IGF axis. 
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Materials and Methods 
 
Mice and Diets 
 All animal protocols and procedures used in this study were approved by the 
Institutional Animal Care and Use Committees at Cornell University and conducted in 
accordance with the Guide for the Care and Use of Laboratory Animals (protocol 
number 2001-0034). The Dlx3+/− mice were a generous gift from Dr. Maria Morasso 
(NIH/NIAMS) and were genotyped using a three-primer duplex PCR (polymerase 
chain reaction) of tail DNA. The primers were designed to amplify wildtype or 
knockout allele amplicons or both (indicating a heterozygote) (Supplementary Table 
S1). The mice were housed in microisolator cages (Ancare) in an environmentally-
controlled room (22–25 °C and 70% humidity) with a 12-h light-dark cycle. Breeding 
animals were given ad libitum access to commercial rodent chow (Teklad) and water. 
Female Dlx3+/− mice were mated with Dlx3+/− males. Female and male offspring 
were genotyped at time of weaning (three weeks of age), and Dlx3+/− animals were 
given ad libitum access to an AIN-93G purified rodent diet (Dyets #103345) 
containing 1.4 g choline chloride/kg diet (1X choline control diet). Five days before 
mating with Dlx3+/− males, Dlx3+/− females (n = 116) were randomized to receive 
either the 1X choline control diet (1.4 g/kg, the standard choline content of the AIN-
93G diet providing adequate choline intake), a 2X choline diet containing 2.8 g 
choline chloride/kg (Dyets #103346), or a 4X choline diet containing 5.6 g choline 
chloride/kg (Dyets #103347). The 2X treatment was chosen to correspond with the 
previous human feeding study conducted by our research group [19]. A 4X treatment 
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is widely used to investigate cognitive effects in rodent models. The presence of a 
vaginal plug was used to designate embryonic (E) day 0.5. Pregnant mice were 
euthanized at four different gestational time points (E10.5, E12.5, E15.5, and E18.5) in 
order to assess the effects of maternal choline supplementation across gestation. 
 
Tissue Collection and Processing and Fetal Anthropometry 
 At the time of dissection, the maternal liver was removed, flash frozen in liquid 
nitrogen, and stored at −80 °C. The number of implantations and resorptions in the 
gravid uterus were recorded. Embryos and placentas were carefully dissected to 
minimize decidual contamination and weighed. At E12.5, E15.5, and E18.5, placentas 
were bisected across the chorionic plate; half was placed in RNAlater for mRNA 
analysis, while the remaining half was immediately frozen in liquid nitrogen and 
stored at −80 °C for metabolite analysis. Due to the smaller tissue size, E10.5 
placentas were alternately designated for mRNA analysis or metabolite analysis. 
Fetuses were imaged and subsequently frozen in liquid nitrogen and stored at −80 °C. 
The crown rump measurement of the fetuses was calculated from images using ImageJ 
software (NIH). Fetal DNA was extracted for Dlx3 genotyping and sex determination 
using a commercial kit (Qiagen Inc., Germantown, MD, USA). Sex genotyping was 
performed by PCR for the Sry gene with a commercial kit (Qiagen Inc., Germantown, 
MD, USA). The primers are listed in Supplementary Table S1. 
 Fetal body composition analyses were determined on fetuses acquired from 
E18.5 using the Leshner method [20]. Fetuses were decapitated at dissection to allow 
for analyses of the brain in a separate study; all body composition data is reported on 
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the remaining tissue. Briefly, the fetuses were thawed and weighed, followed by 
desiccation to determine water weight. Dehydrated fetuses were weighed and 
pulverized before undergoing ethyl ether/methanol total lipid extraction. Total lipid 
extractions were successively performed until no change in weight occurred. The 
protein content was determined colorimetrically, following the digestion of pulverized 
fetal tissue in radioimmunoprecipitation assay (RIPA) buffer. 
 
Measurements of Hepatic and Placenta Metabolites 
 Concentrations of choline and the related metabolites betaine, methionine, 
phosphocholine, glycerophosphocholine, phosphatidylcholine, 
lysophosphatidylcholine, and sphingomyelin were measured in the maternal livers of 
dams by LC-MS/MS (liquid chromatography–tandem mass spectrometry) according 
to the method of Koc et al. [21], with modifications based on our equipment [19]. 
Choline, betaine, and methionine in the placenta were measured using the method of 
Holm et al. [22], with modifications based on our equipment [19]. 
 
Quantitative Real-Time RT-PCR 
 RNA was extracted from placentas fixed in RNAlater using TRIzol reagent 
(Invitrogen, Waltham, MA, USA). Two or three placentas per dam were randomly 
selected for extraction. RNA concentration and quality were assessed with a 
NanoDrop ND-1000 instrument (Thermo Fisher Scientific, Waltham, MA, USA), and 
all samples had an A260/A280 ratio ≥1.8. Reverse transcription was performed using 
the ImProm-II Reverse Transcription System (Promega Corporation, Madison, WI, 
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USA). Quantitative PCR was performed using SYBR® Green in a Roche 
LightCycler480. All primers for the targeted genes (Igf1, Igf2, Igf1r, Igf2r, Egfr) were 
designed using NCBI Primer-BLAST (Supplementary Table S1). The reaction 
conditions were as follows: 95 °C for 5 min, followed by 40 cycles with 15 s at 95 °C, 
30 s at 63 °C, and 30 s at 72 °C. A melting curve analysis was included at the end of 
the amplification cycles to ensure the specificity of the PCR product. Fold changes 
were calculated by the ΔCt method [23] normalized to the expression level of 
housekeeping gene Tbp (TATA box binding protein). Tbp has been shown to be stable 
in response to various choline treatments [24]. 
 
Statistical Analysis 
 For maternal measurements, data were analyzed using general linear models 
with treatment and litter size as independent variables. Comparisons between 
embryonic genotype distributions were made using Fisher’s exact test with two-tailed 
P values. For placental and fetal measurements, data were analyzed using a linear 
mixed model. The model included choline treatment, fetal sex, and litter size as fixed 
effects and maternal identifier as a random effect. Data was either stratified by fetal 
Dlx3 genotype or, when all genotypes were combined, was adjusted for fetal genotype 
as a fixed effect. Data were assessed for normality and log-transformed if the residuals 
were not normally distributed. Corrections for multiple analyses were not performed 
due to the hypothesis-driven nature of the study and the relatively limited sample size. 
Data are presented as mean ± SEM. p ≤ 0.05 was considered statistically significant, 
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and 0.05 < p < 0.10 was considered to indicate trends. All analyses were performed 
using SPSS software, Version 23 (IBM). 
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Results 
Effects of Maternal Choline Supplementation 
Pregnancy Outcomes 
 To determine whether choline treatment during pregnancy could improve 
viability, we examined indicators of embryo survival. MCS did not significantly 
impact the number of implantations or the percentage of resorptions at any gestational 
time point in Dlx3+/− litters (Supplementary Table S2). We also assessed whether 
MCS could increase or prolong the survival of homozygous null fetuses at E10.5 and 
E12.5 (Supplementary Table S3). A small number of Dlx3−/− fetuses (n = 10) 
survived to E12.5, with the majority of these found in the 4X group (n = 7). Choline 
treatment at 2X or 4X did not significantly alter embryo genotype distributions at any 
gestational time point. 
 
Fetal and Placental Growth 
 Since Dlx3+/− has been reported to be a model of placental insufficiency, we 
sought to determine whether MCS could improve placental efficiency as well as fetal 
growth. At E10.5, embryo weight was ~70% higher in 4X choline pups of all three 
genotypes compared to 1X controls (p < 0.001, 0.001, 0.033 for wildtypes, 
heterozygotes, and homozygous nulls, respectively). 2X (versus 1X) choline also 
yielded significantly higher embryo weights in wildtype pups (p = 0.038) (Figure 1A). 
At E18.5, the embryo weight of the 4X pups was slightly (but significantly) lower in 
both wildtype (~12%, p = 0.003) and heterozygote (~10%, p = 0.005) pups compared 
to 1X pups (Figure 1B). 
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Figure 1. Fetal and placental growth characteristics by choline treatment (1X control, 
2X, and 4X) and Dlx3 genotype. Embryo weight at (A) E10.5, and (B) E18.5. 
Placental weight at (C) E10.5, and (D) E18.5. Crown-rump length at (E) E10.5 and (F) 
E18.5. Placental efficiency (defined as embryo weight/placental weight) at (G) E10.5 
and (H) E18.5. Data were analyzed using mixed linear models controlling for maternal 
identifier, fetal sex, and litter size. Values are presented as mean ± SEM. Differing 
letters denote p ≤ 0.05. † denotes p < 0.10. n = seven to 10 dams per treatment per 
time point. 
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 Placental weight was significantly higher at E10.5 in 4X heterozygotes (~24%, 
p = 0.024 versus 1X) and tended to be higher in 4X wildtypes (~23%, p = 0.053 versus 
1X) (Figure 1C). Placental weight was not influenced by choline treatment at E18.5 
(Figure 1D). Fetal crown-rump length was ~14% higher at E10.5 in 4X choline 
wildtypes (p = 0.022) and heterozygotes (p = 0.033) compared to 1X controls but did 
not differ at E18.5 (Figure 1E,F). Placental efficiency, calculated as the ratio of 
embryo weight to placental weight, was ~51% higher at E10.5 in 4X choline 
heterozygotes (p = 0.016, vs. 1X) and tended to be higher in wildtypes (~31%, p = 
0.088 vs. 1X) and homozygous nulls (~70%, p = 0.076 versus 1X) (Figure 1G). At 
E18.5, placental efficiency was ~15% lower in 4X wildtypes (p = 0.045 vs. 1X) but 
did not differ in heterozygotes (Figure 1H). 
 At E12.5 and E15.5, the 2X and 4X choline groups of all genotypes did not 
significantly differ from 1X controls in embryo weight, placenta weight, crown-rump 
length, or placental efficiency (Supplementary Table S4). However, when comparing 
2X to 4X, heterozygotes in the 4X group had slightly lower embryo weights at E12.5 
(~19%, p = 0.011). 
 We also assessed the impact of altered growth patterns on fetal body 
composition at E18.5. Choline treatment at 2X or 4X did not alter the percentage of 
body water, fat, or protein compared to 1X choline (Supplementary Table S2). 
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Hepatic and Placental Choline Metabolites 
 Since the maternal liver is the source of choline metabolites, which are used by 
the placenta to support fetal growth and development, we measured the concentration 
of maternal hepatic choline metabolites (Table 1). At all four gestational time points, 
4X (versus 1X) choline yielded significantly higher betaine concentrations by ~112%, 
~114%, ~92%, and ~348% respectively (p < 0.001 for E10.5, 12.5 and 18.5; p = 0.001 
for E15.5). 2X choline yielded higher betaine (~153% of 1X choline) at E18.5 (p = 
0.022 vs. 1X). In the 1X control group, hepatic betaine concentration declined by 
~35% from E10.5 to E18.5 (p = 0.042), whereas the 2X and 4X choline groups 
showed no significant change in hepatic betaine concentrations across gestation. 
At E12.5, glycerophosphocholine (GPC) was lower in both the 2X (~21%, p = 0.031) 
and 4X choline groups (~22%, p = 0.025) compared to the 1X choline group. No 
significant differences in GPC at E10.5, 15.5, or 18.5 were detected. At E15.5, 
phosphocholine was 133% higher in the 4X versus 1X choline group (p = 0.014). No 
significant differences in hepatic choline, methionine, phosphatidylcholine, 
lysophosphatidylcholine, and sphingomyelin were detected at any gestational time 
point (Table 1). 
 Placental concentrations of betaine were also higher in the 4X group at E10.5 
(~39%, p = 0.007 vs. 1X) and tended to be 19% higher at E12.5 (p = 0.088 vs. 1X) 
(Table 2). However, betaine concentration did not differ by treatment in late 
pregnancy (E15.5 and E18.5). Placental concentrations of free choline and methionine 
were not significantly affected by choline treatment at any time point; however, 
methionine tended to be lower at E18.5 in the 4X group (~22%, p = 0.088, versus 1X). 
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Table 1. Maternal liver concentrations of choline metabolites (per gram tissue) at 
E10.5, E12.5, E15.5, and E18.5 by choline treatment. Data were analyzed using 
general linear models with treatment and litter size as fixed factors. Values are 
presented as mean ± SEM. Log-transformed variables are represented by back-
transformed means and 95% confidence intervals (in parentheses). * Significantly 
different versus control diet, p ≤ 0.05. ** Significantly different versus 1X and 2X 
diets, p ≤ 0.05. GPC, glycerophosphocholine; GPC, phosphatidylcholine; PCho, 
phosphocholine; LPC, lysophosphatidylcholine; SM, sphingomyelin. n = seven to 10 
dams per treatment, per time point. 
 
 
 
 
 
 
 
 
 
 
 
 
Time 
point 
Diet 
Choline 
(nmol/g) 
Methionine 
(nmol/g) 
GPC 
(nmol/g) 
LPC 
(nmol/g) 
Betaine 
(µmol/g) 
PCho 
(µmol/g) 
PC 
(µmol/g) 
SM 
(µmol/g) 
10.5 1X 214 (173, 265) 124 (95, 161) 948 ± 105 332 (269, 411) 0.81 ± 0.1 1.03 ± 0.2 22.2 ± 0.9 3.94 ± 0.2 
 2X 242 (186, 313) 92.7 (67, 127) 1021 ± 126 326 (252, 421) 1.49 ± 0.2* 1.41 ± 0.2 21.6 ± 1.1 3.70 ± 0.2 
 4X 247 (197, 310) 99.1 (75, 131) 895 ± 110 347 (277, 435) 1.71 ± 0.1* 1.07 ± 0.2 22.2 ± 0.9 4.16 ± 0.2 
          
12.5 1X 206 (173, 245) 85.5 (70, 104) 865 ± 54 363 (302, 437) 0.99 ± 0.1 1.08 (0.7, 1.6) 22.6 ± 0.7 3.97 ± 0.2 
 2X 188 (156, 226) 108 (88, 133) 687 ± 57* 353 (292, 429) 1.77 ± 0.2* 1.20 (0.8, 1.8) 22.5 ± 0.7 4.03 ± 0.2 
 4X 197 (166, 233) 97.5 (81, 118) 687 ± 52* 371 (308, 446) 2.13 ± 0.1* 1.38 (1.0, 2.0) 22.5 ± 0.7 3.75 ± 0.2 
          
15.5 1X 138 (116, 163) 88.7 ± 5.9 294 (225, 382) 339 (259, 443) 1.21 ± 0.2 0.70 ± 0.2 22.4 ± 0.8 3.44 ± 0.2 
 2X 133 (111, 160) 88.7 ± 6.4 337 (252, 449) 322 (245, 424) 1.60 ± 0.2* 0.73 ± 0.3 21.6 ± 0.8 3.43 ± 0.2 
 4X 144 (121, 171) 75.6 ± 6.0 262 (200, 344) 318 (243, 414) 2.32 ± 0.2* 1.63 ± 0.3* 22.3 ± 0.8 3.20 ± 0.2 
          
18.5 1X 117 (97, 141) 104 ± 7.1 301 ± 34 286 (231, 355) 0.53 ± 0.2 0.58 ± 0.2 22.3 ± 1.0 3.10 ± 0.1 
 2X 141 (116, 170) 83.3 ± 7.2 302 ± 34 262 (211, 325) 1.34 ± 0.2* 1.04 ± 0.2 21.3 ± 1.0 3.23 ± 0.1 
 4X 137 (113, 168) 97.4 ± 7.6 257 ± 36 252 (200, 316) 2.35 ± 0.3** 0.91 ± 0.2 20.8 ±1.0 2.94 ± 0.1 
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Table 2. Placental concentrations of choline metabolites (µmol metabolite/g tissue) at 
E10.5, E12.5, E15.5, and E18.5 by choline treatment. Data were analyzed using mixed 
linear models with treatment, genotype, sex, and litter size as fixed effects and 
maternal ID as random effect. Values are presented as mean ± SEM. * Significantly 
different versus control diet, p ≤ 0.05. ** Significantly different versus 1X and 2X 
diets, p ≤ 0.05. # p < 0.1 vs. 1X diet. n = 20 placentas per treatment per time point 
(two to three per dam). 
 
 
Time 
point 
Diet Choline Methionine Betaine 
E10.5 1X 0.50 ± 0.04 0.27 ± 0.02 3.09 ± 0.24 
 2X 0.56 ± 0.04 0.30 ± 0.02 3.31 ± 0.27* 
 4X 0.52 ± 0.05 0.29 ± 0.03 4.28 ± 0.31** 
     
E12.5 1X 0.65 ± 0.06 0.25 ± 0.03 5.34 ± 0.50 
 2X 0.62 ± 0.06 0.23 ± 0.03 5.59 ± 0.51 
 4X 0.57 ± 0.05 0.25 ± 0.02 6.33 ± 0.42# 
     
E15.5 1X 0.90 ± 0.06 0.19 ± 0.02 7.99 ± 0.40 
 2X 0.94 ± 0.06 0.21 ± 0.02 8.74 ± 0.43 
 4X 0.87 ± 0.07 0.19 ± 0.02 8.27 ± 0.48 
     
E18.5 1X 1.08 ± 0.08 0.200 ± 0.02 7.66 ± 0.46 
 2X 1.14 ± 0.07 0.182 ± 0.02 7.42 ± 0.41 
 4X 1.03 ± 0.08 0.156 ± 0.02# 7.80 ± 0.42 
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Placental Growth Factor Gene Expression 
 Since changes in fetal and placental growth were seen with choline treatment 
at E10.5 and E18.5, we measured the mRNA expression of several key growth-related 
genes in Dlx3+/− placentas at these time points. The placental expression of Igf1 in the 
4X (versus 1X) choline group was ~52% lower at E10.5 (p = 0.005) and, although not 
significant, was also lower (~34%) at E18.5 (Figure 2A). The placental expression of 
Igf2 did not significantly differ at either time point (Figure 2B). Igf1r tended to have 
slightly higher expression (~35%) at E10.5 in the 4X choline group when compared to 
the 1X (p = 0.087) and 2X groups (p = 0.059) (Figure 2C). Similarly, the expression of 
Igf2r was higher (~22%) at E10.5 in the 4X groups compared to 1X (p = 0.035) 
(Figure 2D). Neither Igf1r nor Igf2r was significantly affected by choline treatment at 
E18.5. The expression of Egfr tended to be ~27% lower in the 4X choline treatment 
group at E18.5 versus the 1X controls (Figure 2E). 
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Figure 2. mRNA abundance of (A) Igf1, (B) Igf2, (C) Igf1r, (D) Igf2r, and (E) Egfr at 
E10.5 and E18.5 by maternal choline treatment (1X control, 2X, and 4X) in Dlx3+/− 
placentas. Fold changes are expressed relative to the housekeeping gene Tbp, with the 
1X control group normalized to 1.0. Data were analyzed using mixed linear models 
controlling for maternal ID, fetal sex, and litter size. Log-transformed data (Igf1 at 
E10.5) is represented by back-transformed means and 95% confidence intervals. All 
other values are presented as mean ± SEM. Differing letters denote p ≤ 0.05. † denotes 
p < 0.10. n = 20 placentas per treatment per time point (two to three per dam). 
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Effects of Dlx3 Genotype 
Fetal and Placental Growth 
 No significant differences in embryo weight, placenta weight, crown rump 
length, or placental efficiency were detected between wildtype and heterozygote pups 
at E10.5, 12.5, or 15.5. At E18.5, heterozygous pups weighed ~2% less (p = 0.044) 
and tended to have ~6% lower placental efficiency than wildtypes (p = 0.077) 
(Supplementary Figure S1A,B). Homozygous null pups weighed ~30% less than 
wildtypes and heterozygotes at E10.5 (p < 0.001) and ~59% less at E12.5 (p < 0.001) 
(Supplementary Figure S1C). They also had ~7% to 8% shorter crown rump lengths 
than wildtypes and heterozygotes at E10.5 (p < 0.001) and were ~23% to 25% shorter 
by E12.5 (p < 0.001) (Supplementary Figure S1D). Their placentas were ~31% to 32% 
less efficient than wildtypes and heterozygotes at E10.5 (p < 0.002) and ~52% to 53% 
less efficient at E12.5 (p < 0.001) (Supplementary Figure S1E). Homozygous null 
placentas did not differ in weight compared to wildtypes and heterozygotes at E10.5 
(Supplementary Figure S1F). However, by E12.5, homozygous null placentas weighed 
~17% less than those of wildtypes and heterozygotes (p = 0.027 and 0.019, 
respectively) (Supplementary Figure S1F). 
 
Growth Factor Gene Expression in the Placenta 
 Since we surprisingly observed similar fetal weights in Dlx3 wildtype and 
heterozygous embryos, we also measured growth factor gene expression in E10.5 
wildtype placentas to examine whether this could have resulted from compensatory 
changes in gene expression in Dlx3+/− placentas. Heterozygous pups overall had 
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~75% higher expression of Igf1 compared to wildtypes (p = 0.002) (Supplementary 
Figure S2A). Igf2, Igf1r, and Igf2r expression did not differ between wildtype and 
heterozygous pups (not shown). Heterozygous placentas had ~43% higher expression 
of Egfr at E10.5 compared to wildtypes (p = 0.003) (Supplementary Figure S2B). 
 
Determinants of Fetal Growth 
Choline Metabolites 
 To determine whether choline metabolites were associated with fetal growth, 
we performed regression analyses of placental metabolites and fetal and placental 
growth parameters, adjusting for choline treatment group, fetal genotype and sex, litter 
size, and maternal identifier (Table 3, highly significant relationships between 
metabolites and growth outcomes shown in Figure 3). Placental betaine at E10.5 was 
positively associated with embryo weight (p = 0.0082, Figure 3A) and crown rump 
length (p = 0.011) and tended to be positively associated with placental efficiency (p = 
0.08). At E15.5, betaine was positively associated with embryo weight and placenta 
weight (p = 0.04, 0.0013, respectively). At E18.5, betaine was positively associated 
with placenta weight (p = 0.0015, Figure 3B) and negatively associated with placental 
efficiency (p = 0.01). 
 At E12.5, choline was positively associated with crown rump length (p = 
0.041) and placental efficiency (p = 0.002, Figure 3C) and tended to be positively 
associated with embryo weight (p = 0.065) while being negatively associated with 
placenta weight (p = 0.0025). At E15.5, choline was negatively associated with 
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embryo weight (p = 0.021) and placenta weight (p = 0.000013, Figure 3D). Choline 
tended to positively associate with crown rump length at E18.5 (p = 0.073). 
At E12.5, methionine was negatively associated with crown rump length (p = 0.01) 
and placental efficiency (p = 0.018) and tended to be negatively associated with 
embryo weight (p = 0.09). 
 
Table 3. Placental concentrations of choline metabolites as determinants of placental 
and fetal growth characteristics at E10.5, E12.5, E15.5, and E18.5. Data were analyzed 
using individual mixed linear models with metabolite, treatment, genotype, and sex as 
fixed effects and maternal ID as a random effect. # p < 0.1, * p ≤ 0.05. 
 
 
 E10.5 E12.5 E15.5 E18.5 
 β P value β P value β P value β P value 
Embryo weight 
Choline 0.0051 0.37 0.040 0.065# -0.171 0.021* -0.025 0.71 
Betaine 0.0019 0.0082* -0.0011 0.61 0.018 0.040* 0.0095 0.42 
Methionine -0.0032 0.75 -0.080 0.090# -0.45 0.11 0.018 0.95 
Placenta weight 
Choline -0.0055 0.64 -0.031 0.0025* -0.068 0.000013* -0.00058 0.94 
Betaine -0.00053 0.721 -0.00092 0.37 0.0059 0.0013* 0.0040 0.0015* 
Methionine -0.018 0.36 0.022 0.35 -0.072 0.25 -0.052 0.10 
Crown rump length 
Choline 0.731 0.38 2.3 0.041* -0.65 0.53 2.1 0.073# 
Betaine 0.262 0.011* 0.063 0.60 0.17 0.18 -0.064 0.76 
Methionine -0.012 0.99 -6.3 0.010* -3.1 0.43 2.7 0.60 
Placental efficiency 
Choline 0.19 0.279 1.3 0.0020* 0.33 0.63 -0.018 0.86 
Betaine 0.042 0.080# -0.045 0.30 -0.017 0.84 -0.43 0.010* 
Methionine -0.039 0.90 -0.23 0.018* -1.8 0.49 6.4 0.13 
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Figure 3. Relationships between placental choline metabolites, placental gene 
expression, and fetal and placental growth characteristics. Graphs present data points 
and regression lines obtained from linear mixed models adjusting for the mother’s ID, 
fetal genotype and sex, and litter size, with the intercept set at average litter size. (A) 
Placental betaine concentrations and embryo weight at E10.5; (B) Placental betaine 
and placental weight at E18.5; (C) Placental choline and placental efficiency at E12.5; 
(D) Placental choline and placental weight at E15.5; (E) Placental Igf1 expression and 
embryo weight at E10.5; (F) Placental Egfr expression and embryo weight at E10.5.
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Expression of Growth Factor Genes 
 We performed regression analyses to determine whether the expression of 
these growth factor genes was associated with our fetal and placental growth data, 
adjusting for choline treatment group, fetal genotype and sex, litter size, and maternal 
identifier (Table 4, highly significant relationships shown in Figure 3). At E10.5, 
placental Igf1 expression was negatively associated with embryo weight and crown 
rump length (p = 0.007 and 0.043 respectively, Figure 3E). Similarly, Egfr expression 
was negatively associated with embryo weight, crown rump length, and placental 
efficiency (p ≤ 0.033 for all, Figure 3F). At E18.5, Egfr expression tended to be 
positively associated with embryo weight (p = 0.077), and Igf2r expression tended to 
be negatively associated with crown rump length (p = 0.099). Placental Igf2 and Igf1r 
expression were not significantly associated with growth outcomes at either time 
point.  
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Table 4. Placental expression of growth-related genes as determinants of placental and 
fetal growth characteristics at E10.5 and E18.5. Data were analyzed using individual 
mixed linear models with gene fold change, treatment, genotype (for E10.5), and sex 
as fixed effects and maternal ID as a random effect. # p < 0.1, * p ≤ 0.05. 
 E10.5 E18.5 
 β P value β P value 
Embryo weight     
Igf1 -0.0063 0.0072* -0.045 0.15 
Igf2 0.00012 0.26 -0.00015 0.26 
Igf1r 0.0021 0.55 0.072 0.12 
Igf2r -0.00025 0.84 -0.12 0.11 
Egfr -0.020 0.0019* 0.14 0.077# 
Placenta weight     
Igf1 -0.0043 0.33 -0.00093 0.82 
Igf2 0.070 0.71 0.000013 0.43 
Igf1r 0.0084 0.20 -0.00033 0.59 
Igf2r -0.0014 0.51 -0.0014 0.14 
Egfr 0.00065 0.096 -0.000080 0.99 
Crown rump length     
Igf1 -0.64 0.043* -0.62 0.20 
Igf2 -0.18 0.21 -0.0013 0.54 
Igf1r 0.072 0.88 0.80 0.28 
Igf2r -0.17 0.33 -0.20 0.099# 
Egfr -1.8 0.033* 2.0 0.13 
Placental efficiency     
Igf1 -0.88 0.24 -0.29 0.57 
Igf2 0.0028 0.39 -0.00019 0.93 
Igf1r -0.10 0.36 1.1 0.17 
Igf2r -0.020 0.60 0.018 0.89 
Egfr -0.57 0.0041* 1.3 0.36 
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Discussion 
 In this study, we show for the first time that maternal choline supplementation 
modulates fetal growth in a model of placental insufficiency, the Dlx3+/− mouse. 
 
Supplementing the maternal diet with extra choline accelerates fetal growth during the 
first half of pregnancy 
 Administering choline at 4X the recommended choline intake throughout 
pregnancy significantly increased embryo weight by mid-gestation (E10.5). This was 
accompanied by significant increases in placental weight, crown rump length, and 
placental efficiency in Dlx3+/− embryos and similar trends in Dlx3+/+ and −/− 
embryos. Notably, homozygous null fetuses at E10.5 in the 4X choline group achieved 
fetal weights and lengths similar to, or greater than, wildtype control diet embryos, 
suggesting a temporary rescue of the Dlx3−/− IUGR phenotype. 
 
This acceleration in fetal growth during early pregnancy does not result in 
overgrowth 
 By E12.5 and E15.5, no differences in placental or fetal size by choline 
treatment group were detected, suggesting that compensatory mechanisms had been 
engaged to attenuate the early acceleration in fetal growth. By late gestation (E18.5), a 
small (~12%) but significant decrease in embryo weight and placental efficiency was 
observed among the 4X (versus 1X) choline group. It is unlikely that the slightly 
smaller weight of 4X embryos compared to controls in the current study would have 
negative health consequences as this decrease did not coincide with any changes in 
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body composition (fat or protein percentage). Additionally, the 4X embryo weights at 
E18.5 were similar to the control group embryo weights at E18.5 in a parallel study 
using a wildtype mouse with the same strain background under identical study 
conditions [9]. 
 
Supplementing the maternal diet with extra choline may uniquely benefit pregnancies 
characterized by placental insufficiency 
 The acceleration in growth during early pregnancy in our Dlx3 mice was not 
observed in a parallel study conducted by our research group in mice without placental 
insufficiencies. Maternal choline supplementation did not significantly affect embryo 
weight at any gestational time point in wildtype mice [9]. This suggests that providing 
extra choline may have a unique effect in mothers with compromised pregnancies who 
are at risk of IUGR. Since a growth-promoting effect was seen in both wildtype and 
Dlx3+/− fetuses, it appears that the mother’s genotype, rather than that of the fetus, is 
responsible. This may reflect the fact that circulating factors produced in dysfunctional 
placentas, such as sFlt-1, are capable of influencing their wildtype littermates. 
 
The main metabolic fate of the supplemental choline in our study was betaine 
 Mothers in both choline groups had higher hepatic betaine levels at all four 
gestational time points. In control mothers, betaine was lower at E18.5 compared to all 
three earlier time points, suggesting a depletion of hepatic stores, which was prevented 
in the choline treatment groups. Placental betaine concentrations were also increased 
by 4X choline at E10.5 and E12.5. The positive association between placental betaine 
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and embryo weight at E10.5, even controlling for choline treatment group, supports 
the role of betaine in promoting early fetal growth in the Dlx3+/− mouse. Notably, the 
placenta does not express the enzyme BHMT (betaine-homocysteine S-
methyltransferase) and therefore cannot use betaine as a methyl donor. However, 
BHMT is expressed in the early embryo [25] and in fetal livers [26]. Thus, a possible 
explanation for improved fetal growth in early gestation may be the enhanced transfer 
of betaine from the placenta to the fetus, allowing its use of the methyl groups. Betaine 
may also reduce osmotic stress [27], which could have contributed to the observed 
improvements in placental efficiency. Nonetheless, inverse associations between 
circulating concentrations of betaine and birth weight have been reported in human 
pregnancy. Higher maternal circulating concentrations of betaine and higher umbilical 
cord betaine and choline have shown possible associations with lower birth weights 
[28,29]. However, one study also found a positive association between cord blood 
dimethylglycine, produced when betaine acts as a methyl donor, and birth weight [29]. 
This suggests that reduced flux through choline metabolic pathways in smaller babies 
may have resulted in higher circulating levels. 
 
Maternal choline supplementation also altered hepatic phosphocholine and GPC 
levels 
 Glycerophosphocholine (GPC) is an intermediate in the breakdown of 
phosphatidylcholine (PC); it has been shown to increase when demand for methyl 
groups is high, as in the case of folate deficiency [30]. At E12.5, mothers in both 
choline treatment groups had lower hepatic GPC levels, suggesting a reduced turnover 
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of PC due to higher choline availability. GPC levels have been shown to be higher in 
preeclamptic placentas and to positively correlate with the preeclampsia risk factor 
sFLT1 [31], indicating that high PC turnover to regenerate methyl groups may be a 
characteristic of this disorder. Phosphocholine is an intermediate in the CDP-choline 
(cytidine diphosphate-choline) pathway; its conversion to CDP-choline is the rate-
limiting step in PC synthesis [5]. At E15.5, 4X mothers had higher hepatic 
phosphocholine concentrations, potentially due to a larger supply of choline being 
directed into the CDP-choline pathway. 
 
Enhanced early growth led to placental downregulation of Igf1 
 The growth promoting role of IGF1 has been demonstrated in knockout mouse 
models [32] and in mouse models of IUGR, whereby Igf1 overexpression corrected 
the placental insufficiency and normalized fetal weight [33]. Human studies of IUGR 
pregnancies show a mixed relationship with IGF1, with some studies reporting higher 
maternal levels of IGF1 in IUGR pregnancies, suggesting compensatory upregulation 
in response to placental insufficiency [14]. Surprisingly, we found lower expression of 
Igf1 in 4X choline placentas at E10.5. In addition, Igf1 expression was inversely 
associated with embryo weight. The expression of Egfr, although not significantly 
altered by choline treatment, was also negatively associated with embryo weight, 
which was unexpected given that a lack of Egfr induces an IUGR phenotype [34]. 
These findings suggest that the observed downregulations of Igf1 and Egfr are 
compensatory mechanisms that occurred in larger embryos to protect against 
excessive growth. A bidirectional relationship between placental Igf1 expression and 
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birth weight has been reported, whereby they are positively correlated in low and 
normal birth weights but inversely correlated in large babies [35]. In this way, Igf1 
may function to prevent extreme fetal weight in both directions. We also detected a 
slight but significant upregulation of Igf2r in 4X placentas at E10.5. As IGF2R 
regulates IGF2 availability by binding it and preventing signaling via IGF1R [36], this 
may represent an additional attempt by the placenta to restrain growth. 
With compensatory mechanisms already occurring at E10.5, it is likely that the 
mechanisms resulting in increased early growth occur before this time. IGF2 controls 
cell proliferation from E9 to E10, resulting in restricted growth by ~E11 if IGF2 is 
disrupted [37]. Therefore, it is possible that choline increased the expression of Igf2 
before E10.5. Although we did not detect significant upregulation of Igf2 at E10.5, 
higher betaine availability combined with the activation of Igf2 by methylation [38] 
supports this gene as a plausible candidate for early growth promotion. Alternatively, 
since the fetus, but not the placenta, is able to use betaine’s methyl groups, early 
modulation of the IGF axis may occur at the level of the fetus. Future studies 
examining gene expression in fetal tissues could assess this hypothesis. 
 
Dlx3+/− placentas had higher expression of growth factor genes 
 Interestingly, Dlx3+/− placentas had higher expression of Igf1 and Egfr at 
E10.5, a possible explanation for the similar weights of wildtype and Dlx3+/− 
embryos, in contrast to a previous study, which found reduced weights in 
heterozygotes compared to wildtypes [11]. Similar compensatory mechanisms via 
IGF1 have been reported in IUGR pregnancies [39,40]. Another possible explanation 
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for the different study findings is the use of a purified AIN-93 diet in the current study 
(in contrast to a standard chow diet), which is specially formulated to support growth 
during pregnancy and may have allowed Dlx3+/− embryos to achieve normal weights. 
The survival of a subset of Dlx3−/− embryos at E12.5 in the 1X control group was 
unexpected and may be another reflection of the quality of the diet. Previously, 
Dlx3−/− embryos were detected at E12.5 only after treatment with TEMPOL, a strong 
antioxidant [11]. 
 
Strengths and Limitations 
 The strengths of our study include the use of four gestational time points, 
allowing a unique view of changes throughout pregnancy, and two supplemental 
doses, allowing the detection of dose-dependent effects. The use of an outbred mouse 
model displaying substantial variation between individuals limited our statistical 
ability to detect significant differences; however, it provided a wide range of responses 
to treatments, which is more similar to a human clinical trial and potentially leads to 
more generalizable findings. A disadvantage of using a mouse model to investigate 
pregnancy is that mouse fetuses are born at a comparatively underdeveloped stage 
compared to humans; thus, direct comparisons to pregnancy complications that occur 
late in gestation are difficult [41]. Our study was limited by the lack of a time point 
prior to E10.5, reducing our ability to determine mechanisms that increased early 
embryo growth. Additionally, our study was not powered to account for the effect of 
fetal sex; however, after determining that it was a source of variation in many 
outcomes, we included it in our statistical model. We were also limited by the high 
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resorption rate and small litter sizes of Dlx3+/− mothers, which restricted our ability to 
perform further assays to assess protein expression and downstream signaling in the 
same cohort. 
 
Conclusions 
 In conclusion, maternal choline supplementation increased fetal and placental 
growth during early-mid gestation in a mouse model of placental insufficiency, 
resulting in compensatory changes to slow growth. The marked increase in embryo 
weight at mid gestation with choline treatment provides support for the potential use 
of choline as an intervention for IUGR, small for gestational age, and placental 
insufficiency. Since many pregnancy complications such as IUGR and preeclampsia 
increase the risk of early delivery [42], increasing fetal growth by mid gestation may 
avoid negative health outcomes for the fetus. In order to understand the future 
potential of maternal choline supplementation as a treatment in humans, further 
research is warranted to assess the effects in early gestation and determine the 
mechanisms by which choline and betaine impact fetal growth. Overall, these data 
show that, in this mouse model of placental insufficiency, supplementing the maternal 
diet with extra choline enhances fetal and placental growth in early-mid gestation 
without leading to major differences in later gestation.
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Supplementary Figure S1. Fetal and placental growth characteristics differ by Dlx3 
genotype. Embryo weight (A) and placental efficiency (B) at E18.5. Embryo weight 
(C), Crown rump length (D), placental efficiency (E), and placental weight (F) at 
E10.5 and E12.5. Placental efficiency defined as embryo weight/placental weight. 
Data were analyzed using mixed linear models controlling for choline treatment, 
maternal ID, fetal sex, and litter size. Values are presented as mean ± SEM. Differing 
letters denotes P ≤ 0.05. † denotes P<0.10.  
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Supplementary Figure 2. Placental mRNA abundance of (A) Igf1 and (B) Egfr at 
E10.5 by Dlx3 genotype. Fold changes are expressed relative to the housekeeping 
gene Tbp with wildtypes normalized to 1. Data analyzed using mixed linear models 
controlling for choline treatment, maternal ID, fetal sex, and litter size. Log-
transformed data (Igf1) is represented by back-transformed means and 95% 
confidence intervals. All other values are presented as mean ± SEM. Differing letters 
denotes P ≤ 0.05.  
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Supplementary Table 1. Primers for genotyping and RT-qPCR. 
 
 
 
 
 
 
 
 
Gene Name Reference 
Sequence 
Primer Sequences Annealing 
Temperature 
Dlx3  
 
Distal-less 
homeobox 3 
NC_000077.6 F: 5’ GTGAACGGCAAGCCCAAA 3’ 
R (Wild type allele): 
5’ CTCTGTGACACGCCATACACAGTT 3’ 
R (Knockout allele): 
5’ AAAGGCCCGGAGATGAGGAAGAG 3’ 
Touchdown 
from 63° to 
49° 
Sry Sex determining 
region Y 
NC_000087.7 F: 5’ TGGGACTGGTGACAATTGTC 3’  
R: 5’ GAGTACAGGTGTGCAGCTCT 3’ 
60°C 
Igf1 Insulin-like growth 
factor 1 
NM_010512.5 
 
F: 5' GACCGAGGGGCTTTTACTTC 3' 
R: 5' CATCCACAATGCCTGTCTGA 3' 
63°C 
Igf2 Insulin-like growth 
factor 2 
NM_010514.3 
 
F: 5' CGCTTCAGTTTGTCTGTTCG 3' 
R: 5' GCAGCACTCTTCCACGATG 3' 
63°C 
Igf1r Insulin-like growth 
factor receptor 1 
NM_010513.2 F: 5' GCTTCGTTATCCACGACGATG 3' 
R: 5' GAATGGCGGATCTTCACGTAG 3' 
63°C 
Igf2r Insulin-like growth 
factor receptor 2 
NM_010515.2 F: 5' TCTGTGTTGGCTCGTCACTC 3' 
R: 5' CCGGTGACAGACGTTGATGA 3’ 
63°C 
Egfr Epidermal growth 
factor receptor 
NM_207655.2 
 
F: 5' GGACTGTGTCTCCTGCCAGAAT 3' 
R: 5' GGCAGACATTCTGGATGGCACT 3’ 
63°C 
Tbp TATA-binding 
protein 
NM_013684.3 F: 5’ AGGAGCCAAGAGTGAAGAACAA 3’ 
R: 5’ AACTTCACATCACAGCTCCCC 3’ 
 
60°C 
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Table S2. Litter size, resorptions, total implantations and fetal body composition in 
litters born to Dlx3+/- dams in response to three different maternal choline treatments 
(1X control, 2X and 4X) at E10.5, E12.5, E15.5 and E18.5. For litter size, 
implantations and % resorptions, data were analyzed using ANOVA. For body 
composition, data was analyzed using mixed linear models controlling for fetal 
genotype, maternal ID, fetal sex, and litter size and represented as % of total body 
weight. Values are presented as mean ± SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
Time point Diet Implantations % Resorptions Litter size 
Fetal water 
content (%) 
Fetal lipid 
content (%) 
Fetal protein 
content (%) 
E10.5 1X 12.3 ± 0.8 43.6 ± 5.7 7.2 ± 1.1    
 2X 12.4 ± 1.0 34.6 ± 6.9 8.3 ± 1.3 - - - 
 4X 13.2 ± 0.9 47.6 ± 6.0 7.0 ± 1.1    
P (Treatment) 0.722 0.731 0.371    
E12.5 1X 10.6 ± 1.0 55.6 ± 6.3 5.1 ± 1.0    
 2X 10.2 ± 1.1 50.2 ± 6.9 5.3 ± 1.1 - - - 
 4X 12.7 ± 1.0 50.6 ± 6.3 6.3 ± 1.0    
P (Treatment) 0.631 0.198 0.804    
E15.5 1X 11.9 ± 1.2 58.0 ± 5.1 4.9 ± 0.6    
 2X 10.6 ± 1.2 60.4 ± 5.1 3.8 ± 0.6 - - - 
 4X 12.4 ± 1.2 51.9 ± 5.1 5.8 ± 0.6    
P (Treatment) 0.100 0.549 0.491    
E18.5 1X 12.8 ± 0.9 52.9 ± 7.8 5.9 ± 0.9 83.8 ± 0.35 0.91 ± 0.8 10.5 ± 1.2 
 2X 11.0 ± 0.9 53.4 ± 7.4 4.8 ± 0.8 83.8 ± 0.33 1.87 ± 0.7 10.7 ± 1.1 
 4X 12.1 ± 0.9 52.0 ± 7.8 5.6 ± 0.9 84.1 ± 0.34 1.27 ± 0.8 11.7 ± 1.2 
P (Treatment) 0.644 0.359 0.991 0.552 0.377 0.437 
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Table S3. Genotype distributions in offspring born to Dlx3+/- dams in response to 
three different maternal choline treatments (control, 2X and 4X) at E10.5, E12.5, 
E15.5 and E18.5. 2-tailed P values; Fisher’s exact test.  
 
 
 
 
 
 
 
 
  Embryo Genotype (%)  
Time point Diet 
 
WT HET NULL 
P value (vs. 
Ctrl) 
E10.5 1X  14 (21.5%) 35 (53.8%) 16 (24.6%)  
 2X  13 (25.0%) 33 (63.5%) 6 (11.5%) 0.20 
 4X  10 (17.2%) 33 (56.9%) 15 (25.9%) 0.86 
  Expected 25% 50% 25%  
E12.5 1X  23 (38.3%) 34 (56.7%) 3 (5.0%)  
 2X  21 (40.4%) 31 (59.5%) 0 (0.0%) 0.35 
 4X  18 (24.3%) 49 (66.2%) 7 (9.5%) 0.17 
  Expected 33% 67% 0%  
E15.5 1X  22 (40.0%) 33 (60.0%) -  
 2X  15 (39.5%) 23 (60.5%) - 1.0 
 4X  24 (39.3%) 37 (60.7%) - 1.0 
  Expected 33% 67% 0%  
E18.5 1X  18 (34.0%) 35 (66.0%) -  
 2X  22 (37.9%) 36 (62.1%) - 0.70 
 4X  15 (30.0%) 35 (70.0%) - 0.68 
  Expected 33% 67% 0%  
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Table S4. 
Embryo weight, placental weight, crown rump length, and placental efficiency by 
Dlx3 genotype at E12.5 and E15.5. Data were analyzed using mixed linear models 
controlling for maternal ID, fetal sex, and litter size. Values are presented as mean ± 
SEM. #P < 0.1 vs. 1X controls. *P < 0.05 vs. 2X. n=7-10 dams per treatment, per time 
point. Values are presented as mean ± SEM.  
 
 
 
 
 
 
 
 
Time point Genotype Diet 
Embryo 
Weight 
Placenta 
Weight 
Crown Rump 
Length 
Placental 
Efficiency 
E12.5 WT 1X 0.080 ± 0.004 0.058 ± 0.003 9.00 ± 0.2 1.48 ± 0.1 
  2X 0.076 ± 0.004 0.054 ± 0.003 8.69 ± 0.3 1.39 ± 0.1 
  4X 0.071 ± 0.004 0.050 ± 0.003# 9.13 ± 0.2 1.49 ± 0.1 
       
 HET 1X 0.076 ± 0.004 0.057 ± 0.003 8.89 ± 0.2 1.49 ± 0.1 
  2X 0.083 ± 0.004 0.053 ± 0.003 8.76 ± 0.2 1.67 ± 0.2 
  4X 0.068 ± 0.004* 0.052 ± 0.003 8.65 ± 0.2 1.35 ± 0.1 
       
 NULL 1X 0.020 ± 0.007 0.037 ± 0.007 5.82 ± 1.0 0.68 ± 0.2 
  2X - - - - 
  4X 0.023 ± 0.004 0.047 ± 0.004 6.64 ± 0.4 0.50 ± 0.1 
       
E15.5 WT 1X 0.39 ± 0.02 0.098 ± 0.005 14.87 ± 0.4 4.14 ± 0.4 
  2X 0.40 ± 0.03 0.084 ± 0.006 15.18 ± 0.3 4.84 ± 0.4 
  4X 0.39 ± 0.03 0.095 ± 0.005 14.88 ± 0.3 4.23 ± 0.4 
       
 HET 1X 0.38 ± 0.02 0.094 ± 0.005 14.65 ± 0.2 4.11 ± 0.2 
  2X 0.42 ± 0.03 0.087 ± 0.006 14.58 ± 0.3 4.80 ± 0.3# 
  4X 0.39 ± 0.02 0.091 ± 0.005 14.91 ± 0.2 4.44 ± 0.2 
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CHAPTER 2 
MATERNAL CHOLINE SUPPLEMENTATION MODULATES PLACENTAL 
MARKERS OF INFLAMMATION, ANGIOGENESIS, AND APOPTOSIS IN A 
MOUSE MODEL OF PLACENTAL INSUFFICIENCY* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*King JH, Kwan ST(C), Yan J, Fomin VG, Levine SP, Wei E, Jiang X, Roberson MS, 
and Caudill MA. Maternal choline supplementation modulates placental markers of 
inflammation, angiogenesis, and apoptosis in a mouse model of placental 
insufficiency, To be submitted. 
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Abstract 
 Introduction: A properly functioning placenta allows efficient transfer of 
nutrients from mother to fetus and promotes fetal growth. Decreased placental 
efficiency is commonly associated with intrauterine growth restriction, preeclampsia, 
and spontaneous abortion. Choline is an essential nutrient that is a precursor for 
several molecules with crucial roles in fetal development: betaine, an osmolyte and 
methyl donor; acetylcholine, a neurotransmitter and signaling molecule; and 
phosphatidylcholine, the most prevalent membrane phospholipid. We previously 
showed that maternal choline supplementation in the Dlx3+/− mouse, a model of 
placental insufficiency, increases fetal and placental growth in mid-gestation. 
 
 Methods: We measured markers of angiogenesis, inflammation, apoptosis, and 
placental structure and development using real-time quantitative PCR, liquid 
chromatography-tandem mass spectrometry, and immunohistochemistry in the 
placentas of Dlx3+/− female mice consuming 1X (control), 2X or 4X the 
recommended intake levels of choline during gestation. Dams were sacrificed at 
embryonic days E10.5, E12.5, E15.5, and E18.5 and placentas were harvested and 
genotyped for sex and Dlx3 genotype.  
 
 Results: 4X choline increased (P<0.05) placental labyrinth size at E10.5 and 
decreased (P<0.05) placental apoptosis in a fetal sex-dependent manner at E10.5 and 
E12.5. Choline supplementation, particularly at the 2X dose, decreased (P<0.05) 
expression of pro-angiogenic genes Eng (E10.5, E12.5, and E15.5) and Vegf (E12.5, 
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E15.5) and pro-inflammatory genes Il1b (at E15.5 and 18.5), Tnfα (at E12.5) and Nfκb 
(at E15.5). 
 
 Discussion: Maternal choline supplementation beneficially modulates markers 
of placental function in a mouse model of placental insufficiency, providing evidence 
that choline may be a useful therapy during pregnancy to mitigate development of 
placental disorders. 
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Introduction 
 Abnormal placental development underlies many pathologies of pregnancy 
including preeclampsia, intrauterine growth restriction (IUGR), and spontaneous 
abortion [1]. These conditions have serious consequences for the mother and fetus and 
few treatments are currently available for their prevention or treatment.  
 Although the etiology of placental insufficiency is not fully understood, an 
imbalance of pro- and anti-angiogenic and inflammatory factors may contribute [1,2]. 
The development of the placenta requires extensive angiogenesis and vasculogenesis, 
and the maternal uterine spiral arteries must be invaded and remodeled by 
cytotrophoblasts to allow for increased perfusion to the fetus [3]. This process requires 
adequate expression of angiogenic and remodeling genes including the vascular 
endothelial growth factor (VEGF) family. Inadequate trophoblast invasion is a 
characteristic of many placental pathologies. When this process is incomplete, blood 
flow to the placenta is compromised, and oxygen supply may be sporadic, leading to 
placental hypoxic injury. Oxidative stress, excessive apoptosis and inflammation 
result, compromising trophoblast function and preventing efficient transfer of nutrients 
[4]. Anti-angiogenic factors in the maternal circulation, including soluble fms-like 
tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng), may contribute to the 
pathogenesis of preeclampsia symptoms including hypertension and proteinuria, and 
can be used as biomarkers or predictors of risk when measured in early gestation [5,6]. 
Together these dysregulated processes interact to contribute to the pathogenesis of 
preeclampsia and IUGR. 
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 The essential nutrient choline is required for synthesis of the neurotransmitter 
acetylcholine, the membrane phospholipid phosphatidylcholine, and the methyl donor 
and osmolyte betaine [7]. These molecules have crucial roles supporting pregnancy 
through cell growth, DNA methylation, and cellular signaling [8]. Choline has 
previously been shown to reduce levels of sFlt-1 in a randomized, controlled feeding 
trial of maternal choline supplementation during the third trimester of pregnancy in 
healthy women [9]. In addition, choline has been shown to modulate inflammation and 
angiogenesis of placental trophoblast cells in culture [10] and wild type mouse 
placenta [11]. Therefore, we hypothesized that choline supplementation would be 
beneficial for pregnancies complicated by placental insufficiency. 
 Dlx3 (distal-less homeobox 3) insufficiency in mice has been shown to result 
in placental insufficiency [12].  This homeodomain-containing transcription factor is 
required for the development of the maternal-fetal interface [13]. Placentas lacking 
one copy of this gene display inadequate vascularization and abnormal development of 
the placental labyrinth, which is the area of nutrient exchange between the mother and 
fetus [12]. Heterozygous embryos are viable but their placentas display abnormalities 
including reduced invasion of trophoblasts and impaired remodeling of maternal spiral 
arteries as well as increased placental oxidative stress and apoptosis [12]. In mice that 
are homozygous null for Dlx3, placental failure occurs between embryonic days 9.5-
12.5 resulting in extremely restricted fetal growth and subsequently death [13]. 
Notably, we have previously shown that maternal choline supplementation in Dlx3+/- 
mice increases fetal and placental weights during mid-gestation in heterozygous 
embryos [14]. 
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 In the present study, we sought to use the Dlx3+/- mouse model of placental 
insufficiency to investigate the effects of maternal choline supplementation on 
markers of placental function during placental insufficiency and explore how these 
effects progressed throughout pregnancy. 
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Materials and Methods 
 
Mice and diets 
 All animal protocols and procedures used in this study were approved by the 
Institutional Animal Care and Use Committees at Cornell University and were 
conducted in accordance with the Guide for the Care and Use of Laboratory Animals. 
Dlx3+/- mice were genotyped using tail DNA with three-primer duplex PCR 
(Supplemental Table 1). Primers were designed to amplify a wild type band, a 
knockout band, or both (indicating a heterozygote). Mice were housed in microisolator 
cages (Ancare) in an environmentally-controlled room (22-25°C and 70% humidity) 
with a 12-hour light-dark cycle. During breeding, mice were given ad libitum access to 
commercial rodent chow (Teklad) and water. Dlx3+/- females were mated with 
Dlx3+/- males and their offspring were genotyped at time of weaning (3 weeks of 
age). Heterozygous pups were given ad libitum access to the 1X choline control diet, 
AIN-93G purified rodent diet, (Dyets #103345) containing 1.4g choline chloride/kg 
diet. Dlx3+/- female mice were randomized five days before mating with Dlx3+/- 
male mice to receive either the 1X choline control diet, the 2X choline diet containing 
2.8g choline chloride/kg (Dyets #103346), or the 4X choline diet containing 5.6g 
choline chloride/kg (Dyets #103347). Embryonic (E) day 0.5 was designated by 
presence of a vaginal plug. Pregnant mice were euthanized at four different gestational 
time points; E10.5, E12.5, E15.5 and E18.5. 
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Tissue Collection and Processing  
 After pregnant dams were sacrificed, embryos and placentas were carefully 
dissected with minimal decidual contamination and weighed. For approximately 1/3 of 
the litter, the fetus was extracted from the implantation site and the remainder was 
fixed in 10% formalin for histological analyses. For the remaining placentas, at 
gestational time points E12.5, E15.5 and E18.5, placentas were bisected across the 
chorionic plate; one half was stabilized in RNAlater for mRNA analysis while the 
remaining half was immediately frozen in liquid nitrogen and stored at -80°C for 
metabolite analysis. Due to smaller tissue size, E10.5 placentas were designated for 
mRNA analysis or metabolite analysis, alternately. Fetal DNA was extracted for Dlx3 
genotyping and sex determination using a commercial kit (Qiagen). Sex genotyping 
was performed by PCR for the Sry gene with a commercial kit (Qiagen). Primers are 
listed in Supplementary Table 1.  
 
Quantitative real-time RT-PCR 
 RNA was extracted from placentas maintained in RNAlater using TRIzol 
reagent (Invitrogen). 2-3 placentas per dam were randomly selected for extraction. 
RNA concentration and quality were assessed with a NanoDrop ND-1000 instrument 
(Thermo), and samples with a A260/A280 ratio above 1.8 were used for 
quantification. Reverse transcription was performed using the ImProm-II Reverse 
Transcription System (Promega). Quantitative PCR was performed using SYBR® 
Green in a Roche LightCycler480. All primers for the targeted genes (Vegfa, Pgf, Eng, 
MMP14, Tnfα, NfκB, Il1b) were designed using NCBI Primer-BLAST (Supplemental 
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Table 1). Reaction conditions were as follows: 95°C for 5 minutes, followed by 40 
cycles with 15 seconds at 95°C, 30 seconds annealing (see Supplementary Table 1 for 
annealing temperatures), and 30 seconds at 72°C. PCR product specificity was 
monitored using melting curve analysis at the end of the amplification cycles. Fold 
changes were calculated by the ΔCt method [15] normalized to the expression level of 
housekeeping gene Tbp (TATA box binding protein), which has previously been 
shown to be stable in placental tissue [16] and in response to varying choline supply 
[17]. At E10.5, due to limited tissue availability, both wildtype and heterozygous 
placentas were used and genotype was included in the statistical model.  
 
LC-MS/MS 
 Concentrations of acetylcholine were measured in the placenta by LC-MS/MS 
according to the method of Holm et al [18] with modifications based on our equipment 
[19]. 
 
Placental Morphometry 
 Placental tissues fixed in 10% formalin were paraffin embedded and sectioned 
at 10µm. Immunohistochemistry was performed on formalin-fixed sections as 
described previously [20]. For analysis of maternal spiral artery areas, placental 
sections were incubated with smooth muscle actin (SMA) antibody (1:50, 
DakoCytomatin, Glostrup, Denmark), followed by secondary antibody. Slides were 
imaged using an Aperio Scanscope (Vista, CA). Maternal spiral arteries were 
manually defined based on staining location and the presence of non-nucleated red 
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blood cells and Aperio ImageScope software was used to quantify area. Data are 
presented as the ratio of artery luminal area to total arterial area. For analysis of 
placental labyrinth area, placental sections were incubated with biotinylated GSL 1-
isolectin B4 (1:100, Vector Laboratories, Burlingame, CA) and 3-amino-9-
ethylcarbazole (AEC; Invitrogen, Carlsbad, CA) and counterstained with hematoxylin. 
Isolectin is a marker of endothelial cells and has been used previously to stain 
vasculature in other mouse tissues. The placental labyrinth compartment was defined 
manually based on staining location and area was calculated using Aperio ImageScope 
software. Data are expressed as mm2 of cross-sectional labyrinth area. 
 
Placental Apoptosis 
 Placental apoptosis was assessed using the terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) assay. A commercial kit (Millipore, 
Billerica, MA) was used according to the manufacturer’s instructions. Sections were 
imaged using an Aperio ScanScope and number of TUNEL-positive cells was 
determined in the decidua and labyrinth by the average number of TUNEL-positive 
cells in several randomly selected fields. Field sizes were as follows: for E10.5, five 
fields of 250x250 μm2, for E12.5, five fields of 350x350 μm2, for E15.5 and E18.5, ten 
fields of 500x500 μm2. 
 
Statistical Analysis 
 For all placental measurements, data were analyzed separately for each 
gestational day using a linear mixed model. The model included choline treatment, 
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fetal genotype, fetal sex, and litter size as fixed effects and maternal identifier as a 
random effect. Fetal sex and fetal genotype were removed from the model when data 
was stratified by sex or genotype. Data is presented as combined sexes (as noted in the 
text) when the same effect was seen in male and female placentas. Data were assessed 
for normality by assessing the distribution of residuals. Corrections for multiple 
analyses were not performed due to the hypothesis-driven nature of the study and the 
relatively limited sample size. Data are presented as means ± SEM.  P ≤ 0.05 was 
considered statistically significant and 0.05 < P < 0.10 was considered to indicate 
trends. All analyses were performed using SPSS software, Version 23 (IBM). 
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Results 
 
Placental morphometry 
 As we previously reported [14], maternal choline supplementation increased 
placental and fetal weights at E10.5 in offspring of Dlx3+/- mice. Because the Dlx3 
model is associated with labyrinth abnormalities, we sought to determine whether 
choline treatment increases placental weight by increasing the size of the labyrinth. At 
E10.5, 4X choline heterozygous placentas had 73% larger labyrinth area vs 2X choline 
(P=0.014), and tended to be ~46% larger than 1X control placentas (P=0.092). At 
E12.5 and 15.5, there were no significant differences in labyrinth size by choline 
treatment. At E18.5, 2X placentas were ~25% smaller compared to 1X controls 
(P=0.037) and tended to be ~20% smaller than 4X choline placentas (P=0.081, Fig. 
1A).  
 Dlx3-/- placentas had ~40% smaller labyrinths at E10.5 versus heterozygous 
placentas (P=0.04). At E12.5, homozygous null placentas were ~59% smaller vs 
heterozygotes (P=0.012) and ~55% smaller vs wildtypes (P=0.019). Wildtype and 
heterozygous placentas did not differ in labyrinth size at any gestational time point; 
however, at E18.5 heterozygous placenta labyrinths tended to be ~14% larger than 
wildtypes (P=0.052, Fig. 1B).  
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Figure 1.   Placental labyrinth area at gestational days 10.5, 12.5, 15.5, and 18.5, by 
choline treatment (A) and fetal Dlx3 genotype (B). Representative images of placental 
labyrinths at E10.5 are shown in (C). Data were analyzed using mixed linear models 
controlling for maternal ID, fetal sex, fetal genotype (for (A)) and litter size. Values 
are presented as mean ± SEM. Differing letters denote P ≤ 0.05. † denotes P<0.1. 
 
1X Choline Control 
4X Choline 
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Placental apoptosis 
 We performed the terminal deoxynucleotidyl transferase dUTP nick end 
labeling assay (TUNEL) to assess placental levels of apoptosis at all four gestational 
time points. At E10.5, choline treatment tended to result in ~96% lower TUNEL 
scores (average # TUNEL-positive cells per field) in the 4X choline placentas 
(P=0.053, versus 1X controls) (Fig. 2A). When split by fetal sex, in both female 
choline treatment groups TUNEL scores were lower vs 1X controls (~56% for 2X, 
P=0.043 and ~65% for 4X, P=0.027) (Fig 2B).  
 At E12.5, 4X choline placentas had ~58% lower TUNEL scores (P=0.048 
versus 1X controls) (Fig. 2A). When split by fetal sex, the effect was significant in 
males (P=0.031, 4X versus 1X) but not females, although a similar non-significant 
trend was seen (Fig. 2C).   
 At E15.5 and E18.5, no differences in TUNEL score were detected between 
choline treatment groups (Fig. 2A).  
 
Placental artery remodeling 
 Because we had previously found an effect of maternal choline 
supplementation on spiral artery remodeling in wildtype mice [11], we investigated 
whether it would have a similar function in a model of placental insufficiency. We 
assessed the luminal ratio of maternal spiral arteries, defined as (luminal area)/total 
arterial area. Luminal ratio did not differ by choline treatment or Dlx3 genotype at any 
gestational time point (data not shown).  
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Figure 2. TUNEL score (calculated as the average number of TUNEL-positive cells 
per field) at E10.5, 12.5, 15.5, and 18.5 by maternal choline treatment (A) and 
stratified by fetal sex at E10.5 (B) and E12.5 (C). Representative images of TUNEL 
staining at E12.5 are shown in (D). Data were analyzed using mixed linear models 
controlling for maternal ID, fetal genotype and sex (for (A)) and litter size. Values are 
presented as mean ± SEM. Differing letters denote P ≤ 0.05. † denotes P<0.1. 
4X Choline 
1X Choline Control 
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Placental expression of angiogenic genes  
 Because altered levels of pro-angiogenic factors have been implicated in the 
development of preeclampsia and other pregnancy disorders, we measured mRNA 
expression of several key modulators of placental angiogenesis throughout pregnancy 
(Fig. 3 A-D). We report the results according to fetal sex, or in all placentas combined 
when the effect was found in both sexes. 
 At E10.5, expression of Eng was ~31% lower in the female 2X choline pups 
versus 1X controls (P=0.029) (Fig. 3A). There were no significant differences in 
Vegfa, Pgf, or Mmp14 expression at E10.5 (data not shown).  
 At E12.5, 2X and 4X choline males had lower expression of Eng vs 1X 
controls (~64% and ~43%, respectively, P=0.005, 0.013). Similarly, male 2X choline 
placentas had ~44% lower expression of Vegfa (P=0.026 versus 1X) (Fig 3B). There 
were no choline treatment differences in Pgf or MMP14 expression at E12.5. 
 At E15.5, expression of Eng in female placentas was ~38% lower in the 2X 
choline group (P=0.002 vs 1X). Similarly, 2X choline female placentas had ~17% 
lower expression of Vegfa vs 1X controls (P=0.031) (Fig. 3C). Expression of Mmp14 
was ~42% lower in female 2X choline placentas (P=0.019, vs 1X) and ~41% lower in 
4X choline placentas (P=0.015, vs 1X). 
 At E18.5, male placentas in the 2X choline group had ~35% higher expression 
of Vegfa versus 1X controls and 4X choline groups (P=0.011 and 0.01, respectively). 
Similarly, expression of Pgf tended to be ~29% higher in 2X choline males vs 1X 
control males (P=0.091) and was ~42% higher versus 4X choline (P=0.091). Male 2X 
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choline placentas also had ~62% higher expression of Mmp14 vs 1X placentas 
(P=0.006) (Fig 3D). Expression of Eng did not differ by choline treatment at E18.5. 
 
Placental expression of inflammatory genes 
 Abnormal regulation of inflammation has been shown in various placental 
pathologies; therefore, we also measured mRNA expression of several major 
inflammatory regulators in the placenta (Fig. 4 A-C). 
 At E10.5, there were no significant differences in Tnfα, Nfκb, or Il1b 
expression between choline treatment groups (data not shown). 
 At E12.5, 2X choline male placentas had lower expression of Tnfα (~57% 
versus 1X) and tended to have lower expression of Nfκb (~50%, P=0.096 versus 1X) 
(Fig. 4A). Expression of Il1b did not differ by treatment (data not shown). 
 At E15.5, female 2X choline placentas had ~33% lower expression of Nfκb vs 
1X controls (P=0.020). Expression of Il1b was ~36% lower in 2X choline placentas of 
both sexes vs 1X controls (P=0.034) and also in males alone (P=0.031) (Fig 4B).  
 At E18.5, expression of Il1b was ~32% lower in 4X choline pups of male and 
female placentas combined (P=0.02). Female 4X choline placentas tended to have 
~39% lower expression of Nfκb vs 1X control females (P=0.058) (Fig. 4C). No 
differences in Tnfα expression were seen between choline groups at E15.5 or E18.5 
(data not shown). 
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Figure 3. Placental mRNA abundance of angiogenic genes at (A) E10.5, (B) E12.5, 
(C) E15.5, and (D) E18.5 by maternal choline treatment. Data are expressed as fold-
change relative to the housekeeping gene Tbp. Data analyzed using mixed linear 
models controlling for fetal genotype (for E10.5), maternal ID, and litter size. Values 
are presented as mean ± SEM. Differing letters denotes P ≤ 0.05. n=20 placentas per 
treatment, per time point. 
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Figure 4. Placental mRNA abundance of inflammatory genes at (A) E12.5, (B) E15.5, 
and (C) E18.5 by maternal choline treatment. Data are expressed as fold-change 
relative to the housekeeping gene Tbp. Data analyzed using mixed linear models 
controlling for fetal genotype (for E10.5), maternal ID, and litter size. Values are 
presented as mean ± SEM. Differing letters denotes P ≤ 0.05. † denotes P<0.10. n=20 
placentas per treatment, per time point.   
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Placental acetylcholine 
 Because acetylcholine has been linked to angiogenic and inflammatory 
signaling in the placenta [21,22], we measured concentration of placental 
acetylcholine throughout gestation. At E12.5, 2X choline placentas had ~136% higher 
concentrations of acetylcholine vs 1X controls (P=0.011) and ~107% higher 
concentrations vs 4X choline placentas (P=0.020). At E10.5, E15.5, and E18.5, 
acetylcholine concentrations did not differ by choline treatment (Fig. 6).  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Placental acetylcholine concentrations (pmol/gram tissue) at E10.5, E12.5, 
15.5, and 18.5 by maternal choline treatment (1X, 2X and 4X choline). Data analyzed 
using mixed linear models controlling for fetal genotype, fetal sex, maternal ID, and 
litter size. Values are presented as mean ± SEM. Differing letters denotes P ≤ 0.05.
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Discussion 
 In this study, we show for the first time that maternal choline supplementation 
can modulate angiogenesis, inflammation, and placental development in a mouse 
model of placental insufficiency, the Dlx3+/- mouse. 
 
Maternal choline supplementation in the Dlx3+/- mouse increases placental labyrinth 
size and decreases placental apoptosis in mid-gestation 
 Because we had previously reported a higher placental weight at E10.5 with 
maternal choline supplementation in Dlx3+/- dams [14], we sought to determine 
whether this effect could be explained by alterations in the size of the placental 
labyrinth or apoptosis levels. Development of the labyrinth region, which facilitates 
nutrient transfer between mother and fetus, is defective in Dlx3-/- animals [13]. This 
was confirmed in the current study, where we found Dlx3-/- placental labyrinths to be 
significantly smaller at E10.5 and E12.5. At E10.5, a high dose of choline (4X the 
recommended intake) resulted in a larger labyrinth size, compared to a 2X choline 
dose. This increase in surface area for nutrient transfer could contribute to the larger 
embryo weights we previously reported in offspring of Dlx3+/- mothers that received 
4X choline supplementation [14]. 
 An additional explanation for the larger placental weights could be the 
decreased levels of apoptosis we found in both choline groups (particularly the 4X 
group), at E10.5 and E12.5. This effect was most pronounced in female placentas but a 
similar non-significant effect in the same direction was observed in males. These 
findings concur with previous results showing reductions in apoptosis with choline 
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supplementation in trophoblast cells and wildtype mice [10,11]. The elevated levels of 
apoptosis in Dlx3+/- placentas had previously been rescued using a strong antioxidant, 
TEMPOL [12]. Although apoptosis is required for normal placental development, 
elevated levels of apoptosis have been reported in preeclamptic and IUGR placentas 
[23–25]. Therefore, a reduction in placental apoptosis in mid-gestation may have 
beneficial effects in reducing risk of developing later placental complications.  
 
Maternal choline supplementation did not alter maternal spiral artery remodeling in 
the Dlx3+/- mouse 
 In a preliminary histological examination of spiral artery remodeling, we did 
not find evidence that maternal choline supplementation altered arterial luminal area 
percentage in the Dlx3+/- mouse. This is in contrast to previous findings in wildtype 
mice, where 4X choline significantly increased luminal area percentage at E10.5, 12.5, 
15.5, and 18.5 [11]. It is possible that the pathological phenotype of spiral artery 
remodeling in Dlx3+/- and Dlx3-/- placentas was too severe to be ameliorated by 
choline supplementation. However, due to the small size of our histology cohort this 
finding should be confirmed in a larger study.  
 Surprisingly, we did not detect any differences in labyrinth size, apoptosis 
levels, or spiral artery remodeling between Dlx3+/+ and Dlx3+/- placentas. We 
previously found that Dlx3+/- fetuses had higher expression of growth factor genes but 
comparable weights versus their Dlx3+/+ littermates when their mothers consumed a 
high quality pregnancy diet [14], suggesting that the Dlx3+/- placenta may activate 
compensatory mechanisms that lead to results similar to wildtype placentas for certain 
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outcomes.  
 
Effects of maternal choline supplementation on placental angiogenic and 
inflammatory gene expression vary by gestational time point and fetal sex 
 Angiogenesis and inflammation have been shown to be dysregulated in 
pregnancy complications including preeclampsia, IUGR, and spontaneous abortion 
[1,26,27]. Because of this, we measured placental mRNA expression of major 
modulators of these processes to determine whether choline can modulate their 
placental expression in the Dlx3+/- mouse.  
 Overall trends seen included the tendency for pro-angiogenic and pro-
inflammatory markers to be downregulated, and the 2X dose frequently having a 
larger effect than that of 4X. 2X maternal choline supplementation reduced expression 
of Tnfα, Nfκb, and Il1b at different gestational time points of pregnancy. Choline 
deficiency has been previously shown to lead to increased expression of pro-
inflammatory cytokines in a placental trophoblast cell culture model [10] and maternal 
choline supplementation has been shown to reduce inflammatory response in pregnant 
rats challenged with lipopolysaccharide [28]. The results seen in the current study with 
a 2X choline dose provide additional support for the role of choline in mitigating 
inflammation. The lack of effect seen with the 4X treatment may reflect a dose 
response curve whereby maternal choline supplementation has an anti-inflammatory 
effect up to a certain concentration beyond which the effect is reduced. One possible 
explanation for this phenomenon could be an increase in production of trimethylamine 
N-oxide, a gut-derived metabolite produced from choline that can induce 
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inflammatory gene expression [29]. Alternatively, since we previously detected a 
strong growth-promoting effect of 4X choline supplementation in Dlx3+/- which 
subsequently resulted in compensatory mechanisms to reduce growth, these 
compensatory mechanisms may have counteracted the effects of choline in this group. 
 The soluble VEGF receptor endoglin (sEng) has been investigated as a 
predictor or clinical indicator of preeclampsia. It has been implicated in the 
pathological development of the disease as an anti-angiogenic factor that prevents 
VEGF from acting on target tissues [5]. Maternal choline supplementation at 2X or 4X 
lowered placental expression of endoglin at E10.5 and E15.5 in female placentas and 
E12.5 in males. These effects were mirrored by similar downregulations of Vegfa, 
which has been shown to be elevated or decreased in preeclamptic patients depending 
on the study [30–32]. It is possible that the larger labyrinth and placenta size at E10.5 
resulted in a decreased need for placental angiogenesis, resulting in downregulation of 
pro-angiogenic factors. Expression of Mmp14, the matrix metalloproteinase that 
cleaves endoglin into its pathogenic soluble form [33], was also significantly lower at 
E15.5 in females but unexpectedly higher at E18.5 in males with 2X choline 
supplementation. A corresponding upregulation of Pgf and Vegfa expression was also 
detected in E18.5 2X choline males, which may have a beneficial role in preventing 
preterm birth as VEGF signaling in late gestation regulates timing of parturition 
[34,35]. 
 The effects of maternal choline supplementation on placental gene expression 
were sex specific, as previously reported in wildtype mouse pregnancy [11]. 
Differential expression of angiogenic factors according to fetal sex has previously 
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been reported in both normal [36] and preeclamptic [37] human pregnancies. 
Although the mechanisms remain unclear, sex-specific differences in epigenetic 
regulation and hormone environment have been suggested to contribute [38,39]. These 
results add to the body of evidence demonstrating that fetal sex should be accounted 
for when examining placental and fetal outcomes during pregnancy.  
 
Maternal choline supplementation increased placental acetylcholine in a non-dose-
dependent manner only at E12.5  
 Because acetylcholine has been reported to play a role in angiogenic [22] and 
inflammatory [21] signaling in the placenta, we hypothesized that choline may be 
modulating gene expression by altering acetylcholine levels. Surprisingly, we did not 
detect an increase in placental acetylcholine concentrations in response to maternal 
choline supplementation at E10.5, E15.5 or E18.5. At E12.5, acetylcholine levels were 
higher in the 2X but not 4X choline group. Previously, we had shown that 2X maternal 
choline supplementation in healthy third trimester women resulted in increased 
acetylcholine concentrations in term placentas, and that 4X choline increased 
acetylcholine concentrations in the fetal brain of wildtype mice [40]. In the current 
study the 2X choline group at E12.5 was influenced by two outliers with extremely 
elevated acetylcholine levels, and therefore this finding should be confirmed in further 
studies.  
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Strengths and Limitations  
 The high degree of variability found in placentas from Dlx3+/- mothers 
resulted in difficulty achieving our planned statistical power levels. Because of this, 
our histological analyses are included as a hypothesis-generating examination of 
choline’s effects in compromised pregnancies which should be confirmed in larger 
cohorts. We decided to control for the effect of fetal sex after determining that it had a 
strong effect many placental outcomes; however, our study was not originally 
powered to account for this.  An additional limitation of the current study was the 
analyses of mRNA content only without concurrent analyses of secreted pro- and anti-
angiogenic peptides. Our original design sought to examine mRNA expression levels 
as a guide to future studies examining secretion profiles of candidate factors.  Our 
study had several considerable strengths, including the use of a standardized diet and 
two different supplemental doses of choline. Examining four gestational time points 
throughout pregnancy allows a more dynamic view of the changes that occur in the 
placenta. Using the mouse as a model of compromised pregnancy has several 
advantages, including the availability of genetic knockout models and the 
hemochorionic structure of the placenta which has similarities to the primate placenta; 
however, because of differences in vascular structure and gestational length, findings 
should be confirmed in larger mammals and humans in the future. 
 
Conclusion 
 In conclusion, maternal choline supplementation modulated placental 
development and function in a mouse model of placental insufficiency, providing 
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evidence that choline may be a useful therapy during pregnancy to prevent or 
overcome development of placental disorders that impact fetal and maternal health. 
Decreases in pro-angiogenic and pro-inflammatory marker expression and placental 
apoptosis are promising findings that align with previous results showing similar 
effects of choline in different experimental models. Since many pregnant women do 
not currently meet the recommended intake levels of choline [41], further research is 
warranted to investigate beneficial effects of choline on human placental function. 
Overall, these data show that supplementing the maternal diet with choline in a mouse 
model of placental insufficiency reduces markers of placental dysfunction, and 
contribute to the body of literature demonstrating the benefits of choline during 
pregnancy.  
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Supplementary Table 1. Primers for genotyping and RT-qPCR. 
 
Gene Name Reference 
Sequence 
Primer Sequences Annealing 
Temperature 
Dlx3  
 
Distal-less 
homeobox 3 
NC_000077.6 F: 5’ GTGAACGGCAAGCCCAAA 3’ 
R (Wild type allele): 
5’ CTCTGTGACACGCCATACACAGTT 3’ 
R (Knockout allele): 
5’ AAAGGCCCGGAGATGAGGAAGAG 3’ 
Touchdown 
from 63° to 49° 
Sry Sex determining 
region Y 
NC_000087.7 F: 5’ TGGGACTGGTGACAATTGTC 3’  
R: 5’ GAGTACAGGTGTGCAGCTCT 3’ 
60°C 
Vegfa Vascular endothelial 
growth factor A 
NM_001025250.3 F: 5' CACTGGACCCTGGCTTTACT 3’ 
R: 5' ACTTGATCACTTCATGGGACTTCT 3’ 
63°C 
Pgf 
(Plgf) 
Placental growth 
factor 
NM_008827.3 F: 5' TGTGCCGATAAAGACAGCCA 3' 
R: 5' TCGTCTCCAGAATAGGTCTGC 3' 
63°C 
Eng Endoglin NM_007932.2 F: 5' ATCAGTTTCCCGTCAGGCTC 3' 
R: 5' GTTCGATGGTGTTGGATGCC 3' 
63°C 
MMP14 Matrix 
metalloproteinase 14 
NM_008608.4 F: 5' GCCCTCTGTCCCAGATAAGC 3' 
R: 5' TTGGTTATTCCTCACCCGCC 3’ 
63°C 
NfκB Nuclear factor of 
kappa light 
polypeptide gene 
enhancer in B cells 1 
NM_008689.2 F: 5' AGCAACCAAAACAGAGGGGA 3' 
R: 5' TTTGCAGGCCCCACATAGTT 3’ 
60°C 
Il1b Interleukin 1 beta NM_008361.4 F: 5' TGCCACCTTTTGACAGTGATG 3' 
R: 5' GCTCTTGTTGATGTGCTGCT 3’ 
60°C 
Tnfα Tumor necrosis 
factor alpha 
NM_013693.3 F: 5’ AAGTTCCCAAATGGCCTCCC 3’ 
R: 5’ TGGTGGTTTGCTACGACGTG 3’ 
 
60°C 
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CHAPTER 3 
MATERNAL CHOLINE SUPPLEMENTATION ALTERS VITAMIN B-12 
STATUS MARKERS IN HUMAN AND MURINE PREGNANCY* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*King JH, Kwan ST(C), Bae S, Klatt KC, Yan J, Malysheva OV, Jiang X, Roberson 
MS, and Caudill MA. Maternal choline supplementation alters vitamin B-12 status 
markers in human and murine pregnancy. To be submitted. 
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Abstract 
Background: Despite participation in overlapping metabolic pathways, the relationship 
between choline and vitamin B-12 has not been well characterized especially during 
pregnancy under conditions of controlled nutrient intake.   
 
Objective: We sought to determine the effects of maternal choline supplementation on 
vitamin B-12 status markers in human pregnancy and in a mouse model of placental 
dysfunction. In humans, associations between common genetic variants in choline-
metabolizing genes on vitamin B-12 status markers were also explored. 
 
Methods: Pregnant women (n=26) consumed either 480 (approximately 1X the 
adequate intake) or 930 mg choline/day (approximately 2X the adequate intake) for 12 
weeks while consuming a controlled diet. Wildtype and Dlx3+/- mice consumed either 
1X, 2X or 4X choline diets and were sacrificed at gestational days 15.5 and 18.5. 
Serum vitamin B-12, methylmalonic acid (MMA), and homocysteine were measured 
in all samples; holotranscobalamin (in humans) and hepatic vitamin B-12 (in mice) 
were also measured.  
 
Results: 2X maternal choline supplementation for 12 weeks in third trimester pregnant 
women resulted in higher levels of the active form of vitamin B-12, 
holotranscobalamin (~24%, P=0.01). Women with genetic variants in choline 
dehydrogenase (CHDH) and betaine-homocysteine S-methyltransferase (BHMT) had 
higher serum MMA concentrations (~31%, P=0.03) and lower holotranscobalamin 
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concentrations (~34%, P=0.03), respectively. A 4X dose of choline decreased serum 
homocysteine concentrations in wildtype mice and in those with placental 
insufficiency (~36% and ~43% respectively, P=0.006, 0.015).  
 
Conclusion: Maternal choline supplementation and genetic variation in choline-
metabolizing genes modulate vitamin B-12 status during pregnancy. A high dose of 
choline can lower homocysteine in mice with placental dysfunction. These findings 
support an interconnected relationship between choline and vitamin B-12 in pregnancy 
and warrant further investigation into functional consequences of these changes. 
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Introduction 
 The interconnected metabolic network referred to as one-carbon metabolism is 
essential for many vital biochemical processes including nucleotide synthesis, DNA 
methylation, and amino acid metabolism [1]. Demand for one-carbon (methyl) 
nutrients, including choline and vitamin B-12, is particularly high during pregnancy 
when cells of the placenta and fetus are undergoing rapid division [2].  
 The essential nutrient choline is a precursor for three metabolites that have 
crucial roles during pregnancy; the neurotransmitter acetylcholine, the membrane 
phospholipid phosphatidylcholine, and the methyl donor and osmolyte betaine [3]. 
Vitamin B-12 acts as a co-factor for two enzymes; methylmalonyl-CoA mutase, which 
converts methylmalonyl-CoA to succinyl-CoA, and methionine synthase, which 
remethylates homocysteine to form methionine. Choline and vitamin B12 are thus 
metabolically interrelated as they are both used to process homocysteine. Specifically, 
the remethylation of homocysteine to methionine is carried out by two enzymes: 
betaine-homocysteine S-methyltransferase (BHMT), which uses the choline 
metabolite betaine as a methyl donor, and methionine synthase (MTR), which uses 
methylcobalamin as a co-factor [1].  
 Notably, a few studies have reported associations between choline and vitamin 
B-12 status. Pregnant women deficient in vitamin B-12 have lower plasma choline 
concentrations [4], while patients receiving total parenteral nutrition exhibit an inverse 
relationship between plasma choline and methylmalonic acid concentrations [5].  
Further, animal studies have reported a vitamin B-12-sparing effect of choline 
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supplementation [6,7]. However, less is known about the effects of supplemental 
choline on biomarkers of vitamin B-12 status during pregnancy. 
 Many pregnant women do not meet the adequate intake for choline of 450 mg/ 
day [8]. Additionally, several common genetic variants in choline-metabolizing genes 
can modulate choline metabolism and increase the requirement for this nutrient and 
folate, a related one-carbon B-vitamin [9–11]. These genes include CHDH (choline 
dehydrogenase), which synthesizes betaine from choline; PCYT1 (phosphocholine 
cytidylyltransferase), the rate-limiting enzyme in phosphatidylcholine synthesis from 
exogenous choline; PEMT (phosphatidylethanolamine N-methyltransferase), which 
produces endogenous phosphatidylcholine and choline, and BHMT.  
 We sought to determine whether maternal choline supplementation or genetic 
variation in choline-metabolizing genes would alter vitamin B-12 status in pregnant 
women.  In addition, because lower maternal vitamin B-12 status and higher 
homocysteine levels are risk factors for several placenta-derived pregnancy 
complications [12–16], we explored the relationship between maternal choline 
supplementation and vitamin B-12 status in a mouse model of placental insufficiency, 
the Dlx3+/- mouse, which shares several common features with placental pathologies 
in humans [17]. 
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Materials and Methods 
 
Human Feeding Study  
Participants and study design 
 The human component of the present study included twenty-six healthy, third-
trimester pregnant women who had participated in a 12-wk randomized choline 
intervention feeding study in 2009-2010 as described in Yan et al [18]. Eligible 
women (26-29 wk gestation, age 21-40) were randomly assigned to consume either 
480 or 930 mg choline per day (380 mg/day from diet, 100 or 550 mg/day provided as 
supplemental choline) for 12 weeks. All meals and beverages (except water) were 
provided throughout the study and women consumed 1 meal per day at the study site 
throughout the work week. The vitamin B-12 content of the study diet was ~6 µg/day 
and participants also consumed a daily prenatal multivitamin containing 2.6 µg of 
vitamin B-12, for a total daily intake of ~8.6 µg/day [19], approximately 3 times the 
RDA for pregnant women. The study protocol was approved by the Institutional 
Review Board for Human Study Participant Use at Cornell University (Ithaca, NY, 
USA) and Cayuga Medical Center (Ithaca, NY, USA) and was registered at 
clinicaltrials.gov as NCT01127022. All participants provided informed consent. 
 
Sample collection and processing 
 Blood and urine samples were obtained from participants at study baseline 
(week 0) and study-end (week 12) as previously described [18]. Serum was obtained 
from fasting (10 hr) blood samples, separated by clotting and centrifugation and stored 
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at -80°C until analysis. Urine samples from a 24-hour period were pooled and the total 
volume was recorded before storage at -80°C.  
 
Biomarker measurements 
 Serum vitamin B-12, serum methylmalonic acid, serum and urinary 
homocysteine, and serum holotranscobalamin were measured as described in Bae et al 
[19]. Briefly, serum vitamin B-12 was measured with an automated 
chemiluminescence immunoassay using an Immulite 2000 instrument (Siemens 
Medical Solutions Diagnostics); serum MMA and homocysteine and urinary 
homocysteine were measured using gas chromatography-mass spectrometry; serum 
holotranscobalamin was measured by the Axis-Shield Active-B12 EIA (Axis-Shield 
Diagnostics) and urinary creatinine was measured with the Dimension Xpand Clinical 
Chemistry system (Siemens Healthcare Diagnostics). 
 
Genotyping 
 PEMT rs7946, CHDH rs12676, PCYT1 rs 939883 and BHMT rs3733890 SNPs 
were genotyped using DNA extracted from buffy coat with the DNeasy Blood and 
Tissue kit (Qiagen). Endpoint genotyping was performed using Applied Biosystems 
TaqMan Genotyping Master Mix and Assay Mix (Thermo Fisher) on a LightCycler 
480 (Roche) as described previously [20]. 
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Mice Feeding Study 
Animals and Diets 
 All animal protocols and procedures used in this study were approved by the 
Institutional Animal Care and Use Committees at Cornell University and were 
conducted in accordance with the Guide for the Care and Use of Laboratory Animals. 
Dlx3+/- mice were a generous gift from Dr. Maria Morasso (NIH/NIAMS). Wildtype 
mice of the same genetic background (non-swiss albino, NSA/CF-1) were purchased 
from Harlan (Indianapolis, IN). Dlx3+/- mice were genotyped using tail DNA with 
three-primer duplex PCR (Supplemental Table 1). Primers were designed to amplify a 
wildtype band, a knockout band, or both (indicating a heterozygote). Mice were 
housed in microisolator cages (Ancare) in an environmentally-controlled room (22-
25°C and 70% humidity) with a 12-hour light-dark cycle. During breeding, mice were 
given ad libitum access to commercial rodent chow (Teklad) and water. NSA females 
were mated with NSA males, Dlx3+/- females were mated with Dlx3+/- males and 
their offspring were genotyped at time of weaning (3 weeks of age). NSA and Dlx3 
heterozygous pups were given ad libitum access to the 1X choline control diet, AIN-
93G purified rodent diet, (Dyets #103345) containing 1.4g choline chloride/kg diet. 
NSA and Dlx3+/- female mice were randomized five days before mating with male 
mice of the same genotype to receive either the 1X choline control diet, the 2X choline 
diet containing 2.8g choline chloride/kg (Dyets #103346), or the 4X choline diet 
containing 5.6g choline chloride/kg (Dyets #103347). Embryonic (E) day 0.5 was 
designated by presence of a vaginal plug. Pregnant mice (n=7-9 per treatment, per 
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genotype) were sacrificed at 2 different gestational time points corresponding to late 
gestation; E15.5 and E18.5. 
 
Sample Collection and Processing  
 Maternal blood was collected by cardiac puncture into microtainer collection 
tubes with clot activator and SST gel (Becton Dickinson), and was allowed to clot at 
room temperature for one hour. After centrifuging at 14,000 rpm for 6 minutes, the 
serum was dispensed into a separate tube and stored at -80°C. Maternal liver was 
removed and bisected; one half was immediately frozen in liquid nitrogen and stored 
at -80°C for metabolite analysis while the other half was preserved in RNAlater for 
RNA extraction. 
 
Quantitation of hepatic vitamin B-12 gene expression via real-time RT-PCR 
 RNA was extracted from livers fixed in RNAlater using TRIzol reagent 
(Invitrogen). RNA concentration and quality were assessed with a NanoDrop ND-
1000 instrument (Thermo), and samples with a A260/A280 ratio above 1.8 were used 
for quantification. Reverse transcription was performed using the ImProm-II Reverse 
Transcription System (Promega). Quantitative PCR was performed using SYBR® 
Green in a LightCycler480 (Roche). Primer sequences for the targeted genes (Bhmt, 
Ahcy, Mtr, Mtrr, Mut, and Mat1a) were obtained from PrimerBank 
(https://pga.mgh.harvard.edu/primerbank/, Supplemental Table 1). Reaction 
conditions were as follows: 95°C for 5 minutes, followed by 40 cycles with 15 
seconds at 95°C, 30 seconds annealing (see Supplementary Table 1 for annealing 
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temperatures), and 30 seconds at 72°C. All PCR products were confirmed to be 
specific using melting curve analysis at the end of the amplification cycles. Fold 
changes were calculated by the ΔCt method [21] normalized to the expression level of 
housekeeping gene Tbp (TATA box binding protein), which has previously been 
shown to be stable in response to different choline treatments [22].  
 
Biomarker measurements 
 Serum homocysteine and methylmalonic acid were measured using a TSQ 
Quantum Access LC-MS system (Thermo Fisher Scientific), adapted from the 
methods of Turgeon et al. and Mineva et al. [23,24]. Serum (50 µL) was incubated 
with internal standards DL-homocystine-d8 (CDN Isotopes) and methyl-d3-malonic 
acid (Toronto Research Chemicals) and dithiothreitol followed by protein precipitation 
with 0.4% formic acid in acetonitrile. The sample was then centrifuged after which the 
supernatant was dried in a SpeedVac concentrator (Savant). After drying, the pellet 
was derivatized for 30 minutes at 60°C in n-butanol with 3N hydrochloric acid. After 
a second drying, the resulting pellet was resuspended in mobile phase (45% 
acetonitrile, 55% formic acid (0.1%) in H2O). Extracts (10 µl) were injected into a 
Hypersil Gold C18 column (100mm x 2.1mm, 3 μm, Thermo Fisher) and separated by 
isocratic elution in 45% acetonitrile and 55% formic acid (0.1%) in H2O at a flow rate 
of 400 µl/min. Monitored MRM transitions in positive mode were: m/z 192- 90, 118 
for homocysteine;  m/z 196- 94, 122 for homocysteine d4; m/z 231- 119, 174 for 
MMA; m/z 234- 122, 178 for MMA d3. Quantification was performed using XCalibur 
software (Thermo Fisher Scientific). 
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 Serum vitamin B-12 was measured with an automated chemiluminescence 
immunoassay by Immulite 2000 according to the manufacturer’s instructions (Siemens 
Medical Solutions Diagnostics). 
 Hepatic vitamin B-12 was measured using an UltiMate 3000 ultra-high 
performance LC (UHPLC) and Q Exactive Quadrupole-Orbitrap MS (Thermo Fisher 
Scientific). Extraction of vitamin B-12 from liver was adapted from the method of 
Oosterink et al. [25]. Briefly, ~0.05 g of liver tissue was weighed and homogenized in 
dithiothreitol, H2O, and internal standard (Biotin-d2 purchased from IsoSciences was 
used as internal standard as in Reuter et al. [26] since isotopically labelled 
cyanocobalamin is not widely available). The extracts were autoclaved at 121°C for 
15 minutes in the presence of sodium cyanide to release the vitamin from tissue and 
convert all forms of vitamin B-12 to cyanocobalamin, which is the most stable form of 
vitamin B-12. Lipids were removed with hexane followed by centrifugation. Proteins 
were precipitated with 10% TCA. Following centrifugation, the supernatant was 
diluted with mobile phase (0.1% formic acid in water) before injecting (10 µl) into an 
XBridge C18 column (50mm x 2.1mm, 2.5 μm, Thermo Fisher). An elution gradient 
of 0.1% formic acid in H2O and methanol at 0.2mL/min was run as follows: 0 min, 
10% methanol; 4 min, 60% methanol; 10 min; 100% methanol; 13 min, 10% 
methanol. MS was operating in positive mode with following settings: sheath gas 
pressure was set at 40; auxillary gas 15; spray voltage 5kV; capillary temperature 
380°C; S-lens RF level 40; heater temperature 100°C. MS2 mode was used for 
detection and quantification of cyanocobalamin, where resolution was set at 35,000; 
AGC target 5e4; isolation window 1 m/z; HCD 25. Inclusion list contained m/z 678.29 
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which represented the doubly charged cyanocobalamin molecular ion, m/z 790.34 for 
doubly charged adenosylcobalamin, and m/z 247.1 for biotin d2. For quantification, 
the most abundant ion was used (m/z 147.09 for cyanocobalamin and m/z 229.1 for 
biotin d2). Quantification was performed using XCalibur software (Thermo Fisher 
Scientific). 
 
Statistical Analysis 
 For human outcomes, general linear models (GLM) were used for analysis; 
baseline values, choline treatment and genotypes were included in the model where 
specified. Due to limited numbers of homozygous variant individuals, women with 
either 1 or 2 copies of the variant allele were grouped for analysis except for rs 7946, 
where 0 and 1 copy were grouped due to a small number of women (n=2) without the 
variant. Age and BMI were investigated as potential confounders but were not retained 
as predictors (P>0.1 in all models). For murine outcomes, data were analyzed using 
general linear models (GLM) with choline treatment and litter size as independent 
variables. Partial correlations controlling for litter size were also tested among vitamin 
B-12 biomarkers and between gene expression fold changes and vitamin B-12 
biomarkers. Partial correlations with P<0.05 are reported.  
 Data were assessed for normality by assessing the distribution of residuals. All 
human serum/urinary vitamin B-12 biomarkers were natural log transformed due to 
deviation from normality or homogeneity of variance and values are reported as 
backtransformed (geometric) means and 95% confidence intervals.  
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 Corrections for multiple analyses were not performed due to the hypothesis-
driven nature of the study and the relatively limited sample size. Data are presented as 
means ± SEM or back-transformed (geometric) means and 95% CIs. P ≤ 0.05 was 
considered statistically significant and 0.05 < P < 0.10 was considered to indicate 
trends. All analyses were performed using SPSS software, Version 23 (IBM). 
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Results 
 
Vitamin B-12 status after choline supplementation in third trimester pregnant 
women 
 To determine whether a higher maternal choline intake would alter vitamin B-
12 status in pregnant women, we analyzed status markers by choline treatment group, 
controlling for baseline concentrations of the vitamin B-12 metabolite. Baseline 
concentrations by choline treatment group are listed in Supplementary Table 2. At 
baseline, women in the 930 mg choline/day group had ~26% lower serum MMA 
levels (P=0.039) and tended to have lower serum homocysteine levels (P=0.053). 
Concentrations of serum vitamin B-12, serum holoTC, serum holoTC:vitamin B-12 
ratio, and urinary homocysteine did not differ by treatment group at baseline 
(Supplementary Table 2).  
At study-end, women in the 930 mg choline/day group had ~24% higher serum 
holotranscobalamin concentrations (P=0.01) and ~22% higher holoTC:vitamin B-12 
ratio (P=0.03) versus women in the 480 mg/day group. Urinary homocysteine tended 
to be higher (~51%, P=0.09) in the 930 mg/day group. Serum vitamin B-12, serum 
MMA, and serum homocysteine did not differ by choline treatment (Table 1).  
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Table 1. Biomarkers of vitamin B-12 status at study end (week 12) by choline 
treatment in third trimester pregnant women with equivalent vitamin B-12 intakes 
under controlled feeding conditions. Data are derived from general linear models 
controlling for baseline status. Values are presented as backtransformed (geometric) 
means and 95% confidence intervals. * denotes a significance difference between 
treatment groups (P<0.05). + denotes a trend (P<0.1). n=12 per treatment group. 
holoTC, holotranscobalamin; MMA, methylmalonic acid. 
 
 
 480 mg choline  
/ day 
930 mg choline  
/ day 
P  
Serum vitamin B-12, pmol/L 428 (374, 492) 445 (385, 513) 0.70 
Serum MMA, nmol/L 206 (182, 234) 197 (172, 225) 0.62 
Serum holoTC, pmol/L 82 (73, 91) 101 (90, 113) 0.01* 
Serum homocysteine, μmol/L 4.2 (3.8, 4.7) 4.4 (4.0, 5.0) 0.58 
Serum holoTC:vitamin B-12 ratio 0.19 (0.17, 0.21) 0.24 (0.21, 0.27) 0.03* 
Urinary homocysteine, μg/mg creatinine 3.2 (2.3, 4.5) 4.9 (3.4, 6.9) 0.09+ 
  
95 
 
 
Influence of genetic variation on vitamin B-12 status in third trimester pregnant 
women 
 To investigate whether genetic variants in choline-metabolizing genes (BHMT, 
CHDH, PEMT, and PCYT1) that modulate choline metabolism would influence 
vitamin B-12 status in pregnancy, we analyzed status markers by maternal genotype. 
After 12 weeks of controlled vitamin B-12 intake, women with 1 or 2 copies of the 
CHDH rs12676 variant had ~31% higher serum MMA levels compared to women 
without the variant (P=0.03, Table 2). Women with 2 copies of the PEMT rs7946 
variant tended to have ~57% higher urinary homocysteine levels versus women with 0 
or 1 copy (P=0.09). Women with 1 or 2 copies of the BHMT rs3733890 variant had 
~34% lower concentrations of serum holotranscobalamin (P=0.03). The PCYT1 
rs939883 variant did not significantly affect any markers of vitamin B-12 status.  
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Table 2. Biomarkers of vitamin B-12 status by maternal genotype in third trimester 
pregnant women after 12 weeks of equivalent vitamin B-12 intakes under controlled 
feeding conditions. Data are derived from general linear models controlling for 
choline treatment. Values are presented as backtransformed (geometric) means and 
95% confidence intervals. * denotes a significance difference between genotypes 
(P<0.05). + denotes a trend (P<0.1). BHMT, Betaine-homocysteine S-
methyltransferase 1; CHDH, choline dehydrogenase; PCYT1, phosphocholine 
cytidylyltransferase; PEMT, phosphatidylethanolamine N-methyltransferase; holoTC, 
holotranscobalamin; MMA, methylmalonic acid. 
 
 
    
Serum 
vitamin B-12, 
pmol/L 
Serum MMA, 
nmol/L 
Serum 
holoTC, 
pmol/L 
Serum 
homocystein
e μmol/L 
Serum 
holoTC:vitamin 
B-12 ratio 
Urinary 
homocysteine, 
μg/mg 
creatinine 
CHDH  
rs12676 
WT 459 (390, 541) 176 (150, 208) 97 (78, 122) 4.4 (3.9, 5.0) 0.21(0.17, 0.27) 3.8 (2.6, 5.5) 
Variant 406 (339, 486) 232 (195, 276) 84 (65, 107) 4.3 (3.7, 4.9) 0.21 (0.17, 0.27) 4.3 (2.8, 6.6) 
P 0.3 0.03* 0.36 0.74 0.99 0.65 
        
PEMT  
rs7946 
WT 423 (345, 520) 214 (177, 258) 94 (73, 123) 4.4 (3.9, 5.0) 0.24 (0.18, 0.31) 3.2 (2.2, 4.6) 
Variant 441 (378, 515) 189 (158, 226) 88 (71, 110) 4.3 (3.8, 4.9) 0.20 (0.16, 0.24) 5.0 (3.4, 7.2) 
P 0.74 0.34 0.69 0.75 0.26 0.09+ 
        
PCYT1 
rs939883 
WT 401 (328, 491) 225 (184, 277) 78 (60, 103) 4.3 (3.7, 5.0) 0.19 (0.15, 0.25) 4.4 (2.7, 7.0) 
Variant 457 (390, 535) 186 (159, 219) 100 (81, 123) 4.4 (3.9, 4.9) 0.23 (0.19, 0.28) 3.8 (2.6, 5.4) 
P 0.32 0.15 0.17 0.84 0.31 0.61 
        
BHMT  
rs3733890 
WT 460 (391, 540) 191 (162, 225) 103 (84, 127) 4.5 (3.9, 5.1) 0.23 (0.18, 0.29) 4.2 (2.9, 6.2) 
Variant 367 (286, 472) 230 (185, 287) 68 (50, 93) 4.4 (3.7, 5.2) 0.19 (0.13, 0.27) 2.8 (1.7, 4.5) 
P 0.13 0.17 0.03* 0.94 0.38 0.16 
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Vitamin B-12 status after choline supplementation in wildtype and Dlx3+/- mouse 
pregnancy  
 To compare the effects of 2X and 4X choline supplementation, and determine 
whether placental insufficiency would influence this effect, we measured vitamin B-12 
biomarkers in pregnant mice fed either 1X control, 2X choline, or 4X choline diets. 
 
Serum homocysteine 
 At E15.5, Dlx3+/- 4X choline dams had ~37% lower concentrations of serum 
homocysteine versus 1X controls (P=0.015); no differences were detected between 2X 
and 4X or 1X and 2X choline groups (P>0.05). Wildtype dams did not differ by 
choline treatment group at E15.5. At E18.5, both wildtype and Dlx3+/- 4X choline 
dams had lower homocysteine concentrations versus 1X choline (~36% and ~43% 
respectively, P=0.006, 0.015) (Figure 1A); no differences were detected between 2X 
and 4X or 1X and 2X choline groups. Serum homocysteine concentrations did not 
differ between wildtype and Dlx3+/- dams at either gestational time point (Fig. 1C).  
 
Serum methylmalonic acid 
 At E15.5, 4X choline dams of both genotypes had higher serum MMA levels 
versus 2X choline dams (~18% and ~28%, respectively, P=0.039, 0.037). Neither 
choline treatment group differed versus 1X controls (P<0.05). At E18.5, no 
differences in MMA concentration were detected by choline treatment (Fig. 1B). 
Dlx3+/- dams had ~19% higher serum concentrations of MMA versus wildtypes at 
E18.5 (P=0.019) but did not differ from wildtypes at E15.5 (Fig. 1C). 
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Figure 1. Functional biomarkers of vitamin B-12 status in pregnant wildtype (WT) 
and Dlx3+/- mice at gestational days 15.5 and 18.5 by choline treatment (control, 2X, 
or 4X). Serum homocysteine at (A) E15.5 and (B) E18.5. Serum MMA at (C) E15.5 
and (D) E18.5. Serum homocysteine (E) and MMA (F) at E15.5 and E18.5 by dam 
genotype. n=7-9 per treatment, per time point. Differing letters denote P<0.05.  
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Serum vitamin B-12 
 At E15.5, 2X choline wildtype dams had ~33% lower serum vitamin B-12 
versus 1X controls (P=0.038). 4X choline dams did not differ versus 1X or 2X choline 
dams (P>0.05). Serum vitamin B-12 did not differ by treatment in wildtype dams at 
E18.5 or at either time point in Dlx3+/- dams (Fig. 2A). There was an extremely 
strong effect of litter size on serum vitamin B-12 (P<0.001). With adjustment for litter 
size, Dlx3+/- dams had ~38% lower serum vitamin B-12 (P=0.011) versus wildtype 
dams (Fig. 2C). Without adjusting for litter size, serum vitamin B-12 in wildtype and 
Dlx3+/- dams did not differ. We confirmed the well-established inverse relationship 
between MMA and serum vitamin B-12 in our mouse cohort; there was a moderate, 
negative partial correlation between these biomarkers (r=-0.471, P=0.001). 
 
Hepatic vitamin B-12 
 Hepatic vitamin B-12 concentrations did not differ by choline treatment group 
or dam genotype at either gestational time point (Fig. 2B, C). As expected, a moderate 
positive partial correlation between serum vitamin B-12 and hepatic vitamin B-12 at 
E18.5 (r=0.330, P=0.029) as well as a moderate negative partial correlation between 
serum MMA and hepatic vitamin B-12 (r=-0.381, P=0.011). 
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Figure 2. Serum and hepatic concentrations of vitamin B-12 in pregnant wildtype 
(WT) and Dlx3+/- mice at gestational days 15.5 and 18.5 by choline treatment 
(control, 2X, or 4X). Serum vitamin B-12 at (A) E15.5 and (B) E18.5. Hepatic vitamin 
B-12 at (C) E15.5 and (D). E18.5. Serum (E) and hepatic (F) vitamin B-12 at E15.5 
and E18.5 by dam genotype. n=7-9 per treatment, per time point. Differing letters 
denotes P<0.05.  
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Maternal hepatic gene expression after choline supplementation in wildtype and 
Dlx3+/- mouse pregnancy 
 To determine whether changes in hepatic gene expression were responsible for 
changes in vitamin B-12 biomarker status, we measured the expression of genes of the 
methionine cycle (Ahcy, Bhmt, Mtr, Mtrr, and Mat1a) as well as Mut, which 
metabolizes MMA. 
 There were no differences in mRNA transcript abundance between choline 
treatment groups in either dam genotype group at either time point (data not shown). 
Compared to wildtype dams, Dlx3+/- dams had lower expression of Ahcy at E18.5 
(~26%, P=0.035) and tended to have lower expression of Mut (~27%, P=0.095) at 
E15.5 (data not shown).  
 To determine whether hepatic transcript abundance mirrored serum status, 
correlations between transcript abundance and biomarkers of vitamin B-12 were 
explored. At 18.5, there were significant positive partial correlations of Ahcy 
expression with serum vitamin B-12 (r=0.356, P=0.024) and hepatic vitamin B-12 
(r=0.334, P=0.035). In addition, Bhmt expression was positively correlated with serum 
vitamin B-12 at E18.5 (r=0.408, P=0.009) and Mat1a was positively correlated with 
hepatic vitamin B-12 (r=0.317, P=0.044). 
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Discussion 
 In this study, we show for the first time that maternal choline supplementation 
during pregnancy modifies markers of vitamin B-12 status in both mice and humans. 
Additionally, we report the effects of choline-related single nucleotide polymorphisms 
on vitamin B-12 status in third trimester pregnant women.  
 
Maternal choline supplementation alters markers of vitamin B-12 status in third 
trimester pregnant women 
 A higher maternal choline intake (~2X the adequate intake level) resulted in 
higher serum holotranscobalamin and a higher ratio of serum holotranscobalamin to 
vitamin B-12. Holotranscobalamin is the active form of vitamin B-12 and its ratio to 
vitamin B-12 in serum has been reported to reflect tissue availability [27]. As such, 
choline supplementation may provide increased supply of vitamin B-12 for the mother 
and fetus. A tendency toward higher urinary excretion of homocysteine in the 2X 
choline group was also observed.  This may reflect a greater use of choline-derived S-
adenosylmethionine (SAM) in cellular methylation reactions which yield S-
adenosylhomocysteine (SAH) and homocysteine. Additionally, this may result from a 
higher level of PEMT activity in response to choline supplementation, since this 
reaction produces 3 molecules of S-adenosylhomocysteine.  
 Studies investigating vitamin B-12 status in pregnant women have found 
significant rates of insufficiency that increase throughout gestation, with a recent 
meta-analysis estimating third trimester insufficiency at 29% of pregnant women [28]. 
Because vitamin B-12 is found solely in animal source foods, vegetarian and vegan 
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pregnant women may be at higher risk of inadequacy of this nutrient [29]. These 
findings collectively suggest that a higher intake of choline or its metabolite betaine, 
which is prevalent in plant foods, may be an additional strategy to improve vitamin B-
12 status during pregnancy.  
 
Genetic variants in choline-metabolizing enzymes alter vitamin B-12 status in third 
trimester pregnant women 
 Genetic variants in choline-metabolizing genes have previously been shown to 
modulate choline metabolism and alter susceptibility to choline deficiency [10,11]. 
However, their influence on vitamin B12 status has not been investigated. We found 
that the CHDH rs12676 variant, which can increase susceptibility of choline 
deficiency [10], led to higher levels of serum MMA, a functional indicator of vitamin 
B-12 status. CHDH is responsible for producing betaine from choline; thus a reduction 
in activity of this enzyme may reduce the amount of betaine available for 
remethylation of homocysteine. Consequently, more vitamin B-12 may be needed for 
methionine synthase activity, at the expense of MMA metabolism. Additionally, 
women with 1 or 2 copies of the BHMT rs3733890 variant had lower serum holoTC 
concentrations. This variant has been reported to increase BHMT affinity for betaine 
[30] and decrease turnover of choline to betaine [11]. Since pregnancy itself is another 
factor that decreases the partitioning of choline for betaine synthesis [31], it is possible 
that the partitioning of less choline towards betaine results in an inadequate betaine 
supply for homocysteine remethylation during this reproductive state, thereby 
increasing vitamin B-12 use for methionine synthase activity and reducing circulating 
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serum holoTC. 
 
Maternal choline supplementation alters markers of vitamin B-12 status in pregnant 
wildtype mice and mice with placental insufficiency 
 Because low vitamin B-12 status has been associated with placenta-derived 
pregnancy complications, we sought to determine whether the effect of maternal 
choline supplementation on vitamin B-12 status would differ in mice with placental 
insufficiency. Additionally, we sought to compare the effects of a higher 4X choline 
dose to that of a 2X dose.  
 Maternal choline supplementation at 4X the recommended intake level reduced 
serum homocysteine concentrations in wildtype mice at E18.5 and Dlx3+/- mice at 
E15.5 and E18.5. A 2X choline dose did not result in lower serum homocysteine 
concentrations. Notably, given that the mice in our study were not fasted at time of 
blood collection, the magnitude of the reduction we detected in the 4X group was 
striking and suggests that choline may modulate postprandial homocysteine response 
at high doses.  
 Surprisingly, we observed slightly (but significantly) higher serum MMA in 
the 4X choline group relative to the 2X group. However, serum MMA was quite low 
(~1 nmol/L) in all choline treatment groups. Previous studies in non-pregnant wildtype 
mice also observed negligible levels of MMA, whereas mice with methylmalonic 
acidemia displayed concentrations that were 500x higher [32,33]. Therefore, it is 
unlikely that the slight differences between 2X and 4X choline groups would have 
clinical significance. Nevertheless, despite the low levels we were still able to detect 
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negative partial correlations between MMA and serum and hepatic vitamin B-12, 
consistent with the expected relationship between these biomarkers. 
 We did not detect an effect of maternal choline supplementation on serum or 
hepatic levels of vitamin B-12 at E18.5; whereas at E15.5 2X choline dams had lower 
serum vitamin B-12 versus 1X controls. The placenta accumulates vitamin B-12; 
concentrations are higher than those in the maternal circulation [34]. Therefore, the 
lower serum vitamin B-12 in the 2X choline group at E15.5 in wildtype mice, and the 
lack of differences in hepatic vitamin B-12 levels, may result from greater partitioning 
to the placenta and fetus under conditions of greater availability.  
 Surprisingly, we did not detect any differences by choline treatment in 
expression of Mut or genes of the methionine cycle (Mat1a, Ahcy, Bhmt, Mtr, Mtrr), 
despite choline’s effects on status markers. It is possible that the changes we observed 
in response to choline are regulated post-transcriptionally, reflect changes in non-
hepatic tissue metabolism and gene transcription, or that our sample size was not large 
enough to detect differences in these outcomes.  However, the finding that Ahcy, 
Bhmt, and Mat1a were positively correlated with markers of vitamin B-12 status may 
indicate that higher hepatic methionine cycle activity irrespective of choline treatment 
influenced serum vitamin B-12 biomarkers. 
 
Mice with placental insufficiency have higher serum MMA and lower serum vitamin 
B-12 in late pregnancy 
 Dlx3+/- mice displayed differences in vitamin B-12 status compared with 
wildtype mice at E18.5, suggesting possible effects of the placental insufficiency 
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phenotype on one-carbon metabolism. Lower serum vitamin B-12 combined with 
higher MMA levels both suggest reduced vitamin B-12 availability, which may result 
from wide-spread transcriptional changes induced by Dlx3 haploinsufficiency [35].   
 Unexpectedly, we did not detect higher homocysteine levels in mice with 
placental insufficiency. Additionally, Dlx3+/- mice had lower hepatic expression of 
Ahcy whereas under conditions of hyperhomocysteinemia this enzyme increases in 
activity to carry out the reverse reaction (conversion of homocysteine to S-
adenosylhomocysteine) [36]. This suggests that elevated homocysteine, which is 
commonly observed in women with preeclampsia, is not a feature in the placental 
etiology of the Dlx3+/- placental insufficiency phenotype.  
 
Strengths and Limitations 
 Strengths of the current study include the controlled feeding study design 
which allowed us to assess the effect of maternal choline intake on vitamin B-12 status 
without confounding by vitamin B-12 intake. However, the fact that all women 
consumed adequate intake of vitamin B-12 and achieved vitamin B-12 sufficiency 
means that we cannot extrapolate the effect of choline supplementation to vitamin B-
12 deficient individuals. The greatest effect of choline supplementation in humans was 
on holotranscobalamin status, for which there is currently no available assay for use 
with murine samples. However; assessing effects in mouse pregnancy in addition to 
that of humans allowed us to measure hepatic levels and use a dose of choline not 
previously used in human pregnancy, as well as examine multiple time points of 
pregnancy. The use of the Dlx3+/- model of placental insufficiency further allowed us 
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to explore the relationship between choline and vitamin B-12 in a compromised 
gestational environment.  
 
Conclusions 
 In conclusion, 2X maternal choline supplementation for 12 weeks in third 
trimester pregnant women resulted in higher levels of the active form of vitamin B-12, 
holotranscobalamin, which would be expected to increase vitamin B-12 supply to 
tissues including the placenta and fetus. Additionally, genetic variants in several 
choline-metabolizing genes were found to impact vitamin B-12 status in pregnant 
women. A 4X dose of choline decreased homocysteine levels in wildtype mice and 
those with placental insufficiency. These findings support an interconnected 
relationship between choline and vitamin B-12 and a contribution of choline to the 
methionine cycle even in folate and vitamin B-12 replete individuals. As such, future 
observational and intervention studies may need to consider dietary choline and 
betaine intakes when assessing vitamin B-12 status. Further research is warranted to 
verify these effects in larger populations and those with vitamin B-12 deficiency.  
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Supplementary Table 1. Primers for genotyping and RT-qPCR. 
 
 
Gene Name Reference 
Sequence 
Primer Sequences Annealing 
Temperature 
Dlx3  
 
Distal-less homeobox 3 NC_000077.6 F: 5’ GTGAACGGCAAGCCCAAA 3’ 
R (Wild type allele): 
5’ CTCTGTGACACGCCATACACAGTT 3’ 
R (Knockout allele): 
5’ AAAGGCCCGGAGATGAGGAAGAG 3’ 
Touchdown 
from  
63° to 49° 
Ahcy Adenosylhomocysteinase NM_016661 F: 5’ CCCTACAAAGTCGCGGACATC 3’  
R: 5’ GAGGCTGAGTACATCTCCCG 3’ 
63°C 
Bhmt Betaine-homocysteine S-
methyltransferase 1 
NM_016668 F: 5' TTAGAACGCTTAAATGCCGGAG 3’ 
R: 5' GATGAAGCTGACGAACTGCCT 3’ 
63°C 
Mat1a Methionine 
adenosyltransferase 1 
alpha 
NM_133653 F: 5' GTGCTGGATGCTCACCTCAAG 3' 
R: 5' CCACCCGCTGGTAATCAACC 3' 
63°C 
Mtr 5-methyltetrahydrofolate-
homocysteine 
methyltransferase 
NM_001081128 F: 5' GCTGGTGGACTACATTGACTGGA 3' 
R: 5' TTCTGGCTTCTTCACCTACTGC 3' 
63°C 
Mtrr 5-Methyltetrahydrofolate-
homocysteine 
methyltransferase 
reductase 
NM_172480 F: 5' GGACAGGCAAAGGCCATAG 3' 
R: 5' ACCCGTGGTAGATACAACCAT 3’ 
63°C 
Mut Methylmalonyl-CoA 
mutase 
NM_008650 F: 5' TTTTTGCTATCGCCCCATTACC 3' 
R: 5' CCTCTGGGTTTTTGCCTTTCAG 3’ 
63°C 
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Supplementary Table 2. Vitamin B-12 status markers at baseline (week 0) of 
pregnant women receiving 480 mg or 930 mg choline per day. Differences between 
groups analyzed using general linear models. Values represent geometric means and 
95% confidence intervals. * denotes P<0.05. + denote P<0.1. 
 
 
 
480 mg choline  
/ day 
930 mg choline  
/ day 
P  
Serum vitamin B-12, pmol/L 436 (373, 509) 432 (370, 505) 0.95 
Serum MMA, nmol/L 156 (127, 191) 115 (94, 141) 0.039* 
Serum holoTC, pmol/L 75 (60, 94) 78 (62, 97) 0.82 
Serum homocysteine, μmol/L 4.1 (3.6, 4.6) 3.5 (3.1, 3.9) 0.053+ 
Serum holoTC:vitamin B-12 ratio 0.17 (0.14, 0.22) 0.18 (0.14, 0.23) 0.85 
Urinary homocysteine, μg/mg creatinine 3.0 (2.1, 4.2) 3.8 (2.7, 5.4) 0.33 
